Faculty

Faculty Directory

Professors

Associate Professors

Assistant Professors

Visiting Professors

Associate Members

NOTE: All phone and fax numbers are in the 514 area code unless otherwise indicated.

Professors

Name and email

Phone

Fax

M. Auger; M.D.,C.M. (McG.), F.R.C.P.(C)

Email: manon.auger [at] mcgill.ca (Dr. Manon Auger)

Profile

After obtaining her MD degree at McGill University, Dr. Auger completed her residency training in Anatomical Pathology at the University of Toronto, followed by a Cytopathology Fellowship at the University of Texas M.D. Anderson Cancer Center in Houston.  She is Director of the Cytopathology Laboratory at the McGill University Health Center and is Professor in the Department of Pathology at McGill University. As a leader in the field of cytopathology, currently serves on the Editorial Advisory Board of Cancer Cytopathology, a peer-reviewed journal published by the American Cancer Society.

Special Interests and Research Areas

  • Fine needle aspirations, in particular, those from the thyroid
  • Quality Assurance in gynecologic cytology, including rapid prescreening method
  • Evaluation of the impact of the new Bethesda reporting system on thyroid cytopathology
  • Standardization of diagnostic terminology for urinary cytology
  • Anal cytology
  • History of medicine

Selected Publications

Reply to fine-needle cytology of Hürthle cell tumors and morphometry.
Auger M.
Cancer Cytopathol. 2014 Jul;122(7):553-4

The value of the "suspicious for urothelial carcinoma" cytology category: a correlative study of 4 years including 337 patients.
Ton Nu TN, Kassouf W, Ahmadi-Kaliji B, Charbonneau M, Auger M, Brimo F.
Cancer Cytopathol. 2014 Nov;122(11):796-803

An historic step for advanced cytopathology training in Canada.
Auger M, Islam S, Weir M.
Cancer Cytopathol. 2014 Sep 23

Pulmonary cytology:  blowing new life into diagnostic challenges
Auger M.
Can J Pathol 2014;6 (2):47-56

Hürthle cells in fine-needle aspirates of the thyroid: a review of their diagnostic criteria and significance.
Auger M.
Cancer Cytopathol. 2014 Apr;122(4):241-9

Nongynecologic cytology practice patterns: a survey of participants in the College of American Pathologists interlaboratory comparison program in nongynecologic cytopathology.
Moriarty AT, Nayar R, Auger M, Kurtycz DF, Thomas N, Laucirica R, Padmanabhan V, Souers RJ, Schwartz MR, Fraig MM.
Arch Pathol Lab Med. 2014 Jul;138(7):885-9

A selection of monitoring parameters for gynecologic cytology-Beacons of light for quality assurance.
Auger M.
Cancer Cytopathol. 2014 Jan;122(1):3-4

Implementation of the Bethesda System for Reporting Thyroid Cytopathology: observations from the 2011 thyroid supplemental questionnaire of the College of American Pathologists.
Auger M, Nayar R, Khalbuss WE, Barkan GA, Benedict CC, Tambouret R, Schwartz MR, Howell LP, Souers RJ, Hartley DA, Thomas N, Moriarty AT.
Arch Pathol Lab Med. 2013 Nov;137(11):1555-9

Can the tall cell variant of papillary thyroid carcinoma be distinguished from the conventional type in fine needle aspirates? A cytomorphologic study with assessment of diagnostic accuracy.
Guan H, Vandenbussche CJ, Erozan YS, Rosenthal DL, Tatsas AD, Olson MT, Zheng R, Auger M, Ali SZ.
Acta Cytol. 2013;57(5):534-42

Cytology of spontaneous nipple discharge--is it worth it? Performance of nipple discharge preparations in the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytopathology.
Moriarty AT, Schwartz MR, Laucirica R, Booth CN, Auger M, Thomas NE, Souers RJ.
Arch Pathol Lab Med. 2013 Aug;137(8):1039-42

934-1934
ex. 38772
934-8296

M.N. Burnier Jr.; M.D., Ph.D. (Brazil) 

Email: miguel.burnier [at] mcgill.ca (Dr. Miguel Burnier)
(joint appointment with Opthomology)

Profile

Dr. Miguel Burnier was the Chairman of the Department of Ophthalmology, McGill University, from 1993 to 2008. He is a Full Professor of Ophthalmology, Pathology, Medicine and Oncology at McGill and he was also the Thomas O. Hecht Family Chair in Ophthalmology (1996-2012). This is the first and the only endowment Chair of the Department of Ophthalmology. It was awarded to Dr. Burnier upon his arrival as Professor and Chair of the Department of Ophthalmology. Dr. Burnier is currently the General Director of Clinical Research & Training of the McGill University Health Centre Research Institute.

An extremely active researcher with a particular interest in uveal melanoma, Dr. Burnier is the Director of the Henry C. Witelson Ocular Pathology Laboratory.  The Laboratory is a unique facility in Canada and has become the largest research and training center in Ocular Pathology in North America.  It plays a crucial role as a consultancy service to Pathologists, Ophthalmologists and Oncologists and a teaching facility to medical students, residents and fellows from around the world.  Over 125 fellows from different countries have passed through Dr. Burnier’s lab.

The laboratory offers the only Ocular Pathology graduate program in North America. Since 1999, over 20 graduate students of the Laboratory completed their thesis at the Pathology Graduate Program, McGill University. Also during this time, 30 international graduate students from Federal University of Sao Paulo, Brazil; University of Valladolid and University of Barcelona, Spain and University of Coimbra, Portugal completed their thesis. CEGEP students from Marianopolis College and Dawson College spend a week in the Laboratory as part of a special program to introduce them to research.

Dr. Burnier is the author and co-author of over 500 publications including, 330 peer reviewed papers, 251 peer reviewed abstracts, over 60 publications in various scientific journals, three books and 18 book chapters.  Dr. Burnier has served as Guest Speaker and Visiting Professor at many conferences and symposia across Canada, the United States, Europe and South America. He is an active member of over 20 societies and serves as an Editorial Board Member for Investigative Ophthalmology & Visual Sciences (IOVS). He is also a reviewer for several ophthalmology publications such as, The American Journal of Ophthalmology; Ophthalmology; Cancer and Melanoma Research, and The British Journal of Ophthalmology among others.  Dr. Burnier was the Editor- in- Chief of The Canadian Journal of Ophthalmology from 2002-2005.  Dr. Burnier also holds international appointments such as Professor of Post Graduate Studies and Thesis Supervisor for the Department of Ophthalmology, Federal University of Sao Paulo, Brazil; Professor of Ophthalmology and Pathology, University of Valladolid, Spain; and Professor and Consultant Pathologist for the Armed Forces Institute of Pathology (AFIP) American Registry of Pathology, Washington.

Dr. Burnier has won many awards including The University of Sao Paulo’s Gold Medal in Ophthalmology, The European Ophthalmology Award of Excellence, the American Academy of Ophthalmology Award of Excellence and The Pan American Association of Ophthalmology Life Achievement Award. In research, Dr Burnier received the WHO award for Melanoma research. In 2009, Dr. Burnier received the FARVO medal from the ARVO for his research contributions to the field of Ocular Pathology and Oncology.  Recently, in 2012 Dr. Burnier received The Brazilian Academy of Science Award & Membership in Rio de Janeiro, Brazil.

Among his teaching awards, Dr. Burnier has received the 2006 Gradle Teaching Award given by the American Academy of Ophthalmology/Pan American Association of Ophthalmology. At McGill, Dr. Burnier was named to the Faculty Honour List for Educational Excellence in 2007.  In Canada, Dr. Burnier received the Frederick Feldman Teaching Award from the University of Toronto. Dr. Burnier is the recipient of the Rio Branco Medal, which corresponds to the Order of Brazil. He is also the Chair #45 of the “Academia Ophthalmologica Internationalis.”

In celebration of the 10th Year Anniversary of the Henry C. Witelson Ocular Pathology Laboratory, the Burnier International Ocular Pathology Society (BIOPSY) was founded. The inaugural meeting of the society was in Montreal, May 6-8, 2010.  The second meeting was held in Valladolid, Spain in 2012 and the third meeting was held in Balneario Camboriu, Brazil in April 2014. BIOPSY currently has 120 members and is known for its continuous growth worldwide.

Recent Publications

A cystic epithelial downgrowth mimics an intraocular tumour following penetrating eye trauma.
Jagan LG, Discepola G, Al-Sharif E, Bravo-Filho V, Burnier MN Jr.
Can J Ophthalmol. 2014 Aug;49(4):e94-6.

Expression of focal adhesion kinase in uveal melanoma and the effects of Hsp90 inhibition by 17-AAG.
Faingold D, Filho VB, Fernandes B, Jagan L, de Barros AM Jr, Orellana ME, Antecka E, Burnier MN Jr.
Pathol Res Pract. 2014 Nov;210(11):739-45.

Balloon cell nevus of the iris.
Morcos MW, Odashiro A, Bazin R, Pereira PR, O'Meara A, Burnier MN Jr.
Pathol Res Pract. 2014 Dec;210(12):1160-3

Expression of the metastasis suppressor BRMS1 in uveal melanoma.
Ventura BV, Quezada C, Maloney SC, Fernandes BF, Antecka E, Martins C, Bakalian S, di Cesare S, Burnier MN Jr.
Ecancermedicalscience. 2014 Mar 11;8:410

Case report: an atypical peripapillary uveal melanoma.
Lim LA, Miyamoto C, Blanco P, Bakalian S, Burnier MN Jr.
BMC Ophthalmol. 2014 Feb 3;14:13.

Rapid growth of an orbital hemangiopericytoma with atypical histopathological findings.
Pacheco LF, Fernandes BF, Miyamoto C, Maloney SC, Arthurs B, Burnier MN Jr.
Clin Ophthalmol. 2014;8:31-3.

Hypoxia-inducible factor-1α and its role in the proliferation of retinoblastoma cells.
Fernandes BF, Coates J, Odashiro AN, Quezada C, Huynh A, Odashiro PR, Odashiro M, Burnier MN Jr.
Pathol Oncol Res. 2014 Jul;20(3):557-63. 

Local chemotherapeutic agents for the treatment of ocular malignancies.
Fernandes BF, Nikolitch K, Coates J, Novais G, Odashiro A, Odashiro PP, Belfort RN, Burnier MN Jr.
Surv Ophthalmol. 2014 Jan-Feb;59(1):97-114

934-1934 ex. 38773 398-5728

A. Ferenczy; B.A., B.Sc., M.D. (Montr.)

Email: alex.ferenczy [at] mcgill.ca (Dr. Alex Ferenczy)

340-7526 340-7542

R. Fraser; B.Sc., M.D., C.M. (McG.), M.Sc.(Glas.) F.R.C.P.(C)

Email: richard.fraser [at] mcgill.ca (Dr. Richard Fraser)

934-1934
ex. 43858
934-8296

Z-H. Gao, M.D., Ph.D., F.R.C.P.(C) Chair

Email: zu-hua.gao [at] mcgill.ca (Dr. Zu-hua Gao)

Profile

Dr. Zu-hua Gao obtained his Medical degree from Qingdao Medical College, Masters degree from Harbin Medical University, and PhD degree from Peking Union Medical College.  Dr. Gao received his post-doctoral fellowship training at the Johns Hopkins Hospital, pathology residency training at Dalhousie University, and subspecialty pathology fellowship at the University of Chicago. As a general surgical pathologist, Dr. Gao’s clinical expertise is primarily on diseases of the gastrointestinal tract and liver. As an educator, Dr. Gao teaches pathology courses to undergraduate medical students, and supervises graduate students, residents and fellows. Dr. Gao has written two text books: the LMCC Clinical Skills book for medical students and the Pathology Review book for pathology residents.  As a well-funded research scientist, Dr. Gao has published over 100 peer reviewed articles and over 50 abstracts and meeting presentations. Dr. Gao has received many awards including the Junior Scientist Award in Canada in 2003 and the Distinguished Overseas Scholar Award by the City of Beijing in 2010. As an administrator, Dr. Gao was the Head of Anatomical Pathology and Cytopathology at the University of Calgary,   including 5 university-affiliated hospitals, between 2007-2011. Dr. Gao is currently the Pathologist-in-Chief at the McGill University Health Center which encompases 6 university-affiliated hospitals and the Chair for the Department of Pathology at McGill University which includes 8 university-affiliated hospitals.

Research Interests
Dr. Gao's main areas of research focus on neoplastic and non-neoplastic liver diseases, and colon cancer.

Selected Publications

Sinusoidal endotheliitis as a histological parameter for diagnosing acute liver allograft rejection
Shi Y, Dong K, Zhang YG, Michel RP, Marcus V, Wang YY, Chen Y, Gao ZH.
World J Gastroenterol. 2017 Feb 7;23(5):792-799. doi: 10.3748/wjg.v23.i5.792.

Role of CCN5 (WNT1 inducible signaling pathway protein 2) in pancreatic islets
Liu JL, Kaddour N, Chowdhury S, Li Q, Gao ZH
J Diabetes. 2016 Nov 12. doi: 10.1111/1753-0407.12507

Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma
Li Q, Wang H, Zogopoulos G, Shao Q, Dong K, Lv F, Nwilati K, Gui XY, Cuggia A, Liu JL, Gao ZH
Oncotarget. 2016 Nov 22;7(47):77838-77853. doi: 10.18632/oncotarget.12834.

[Corrigendum] Weighted gene co-expression network analysis of colorectal cancer liver metastasis genome sequencing data and screening of anti-metastasis drugs
Gao B, Shao Q, Choudhry H, Marcus V, Dong K, Ragoussis J, Gao ZH
Int J Oncol. 2017 Jan;50(1):339. doi: 10.3892/ijo.2016.3722. Epub 2016 Oct 6.

Weighted gene co-expression network analysis of colorectal cancer liver metastasis genome sequencing data and screening of anti-metastasis drugs
Gao B, Shao Q, Choudhry H, Marcus V, Dong K, Ragoussis J, Gao ZH.
Int J Oncol. 2016 Sep;49(3):1108-18. doi: 10.3892/ijo.2016.3591. Epub 2016 Jun 30.

Clonal Characteristics of Circulating B Lymphocyte Repertoire in Primary Biliary Cholangitis
Tan YG, Wang YQ, Zhang M, Han YX, Huang CY, Zhang HP, Li ZM, Wu XL, Wang XF, Dong Y, Zhu HM, Zhu SD, Li HM, Li N, Yan HP, Gao ZH
J Immunol. 2016 Sep 1;197(5):1609-20. doi: 10.4049/jimmunol.1600096. Epub 2016 Jul 18.

Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis.
Tretiakova MS, Shabani-Rad MT, Guggisberg K, Hart J, Anders RA, Gao ZH.
Histopathology. 2010 May;56(6):683-93.

Distinction of hepatocellular adenoma from hepatocellular carcinoma with and withoutcirrhosis using E-cadherin and matrix metalloproteinase immunohistochemistry.
Tretiakova MS, Hart J, Shabani-Rad MT, Zhang J, Gao ZH.
Mod Pathol. 2009 Aug;22(8):1113-20.

Intravascular lymphocytosis in acute appendicitis: potential mimicry of chronic lymphocytic leukaemia.
Lee S, Ogilvie RT, Dupre M, Gao ZH.
Histopathology. 2009 Dec;55(6):660-4.

Seeking beyond rejection: an update on the differential diagnosis and a practical approachto liver allograft biopsy interpretation.
Gao ZH.
Adv Anat Pathol. 2009 Mar;16(2):97-117.

Primary hepatic malignant fibrous histiocytoma: clinicopathologic characteristics andprognostic value of ezrin expression.
Li YR, Akbari E, Tretiakova MS, Hart J, Akbari M, Urbanski SJ, Gao ZH.
Am J Surg Pathol. 2008 Aug;32(8):1144-58. 

The impact of pathologist experience on liver transplant biopsy interpretation.
Coffin CS, Burak KW, Hart J, Gao ZH.
Mod Pathol. 2006 Jun;19(6):832-8.

Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors ofmetalloproteinases with the progression and metastasis of hepatocellular carcinoma.
Gao ZH, Tretiakova MS, Liu WH, Gong C, Farris PD, Hart J.
Mod Pathol. 2006 Apr;19(4):533-40.

Repopulation of liver endothelium by bone-marrow-derived cells.
Gao Z, McAlister VC, Williams GM.
Lancet. 2001 Mar 24;357(9260):932-3.

Sirolimus-tacrolimus combination immunosuppression.
McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS.
Lancet. 2000 Jan 29;355(9201):376-7.

934-1934 ex. 38775 934-8296

D. Haegert;M.D. (Br.Col.), F.R.C.P.(C)

Email: david.haegert [at] muhc.mcgill.ca (Dr. David Haegert)

Profile

Dr. David G. Haegert earned his undergraduate degree from the University of Victoria, British Columbia, Canada, and his medical degree from the University of British Columbia. He completed his internship at the Royal Victoria Hospital, Montreal, and his residency training in Anatomic Pathology in the McGill University teaching hospitals. He received post-doctoral training in Immunology at the University of Cambridge, Cambridge, England. Dr. Haegert is a Fellow of the Royal College of Physicians and Surgeons of Canada in Anatomic Pathology. 

Research Interests
Dr. Haegert conducts research focusing on multiple sclerosis and possible biomarkers that predict rates of disease progression in multiple sclerosis and responses to therapy. 
 

Selected Publications

Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS.
Zastepa E, Fitz-Gerald L, Hallett M, Antel J, Bar-Or A, Baranzini S, Lapierre Y, Haegert DG.
Neurology. 2014 Feb 25;82(8):681-90

Castleman's Disease: a rare finding in a pediatric neck.
Zawawi F, Varshney R, Haegert DG, Daniel SJ.
Int J Pediatr Otorhinolaryngol. 2014 Feb;78(2):370-2

Diminished Th17(not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation
Darlington PJ et al (Canadian MS/BMT study group including Haegert DG)
AnnNeurol 2013;73:341-354

Premature thymic involution and multiple sclerosis
Haegert DG.
J Neurol Neurophysiol 5:207, 2014

Multiple sclerosis: a disorder of altered T-cell homeostasis.
Haegert DG.
Mult Scler Int. 2011;2011:461304. 

Reduced thymic output and peripheral naïve CD4 T-cell alterations in primary progressive multiple sclerosis (PPMS).
Haegert DG, Hackenbroch JD, Duszczyszyn D, Fitz-Gerald L, Zastepa E, Mason H, Lapierre Y, Antel J, Bar-Or A.
J Neuroimmunol. 2011 Apr;233(1-2):233-9.

Obstacles to progress in MS: a personal story
Haegert DG.
J Mult Scler 1:e102, 2014

934-1934 ex. 38777 934-8296

Q.A. Hamid; M.D.(Mosul),  Ph.D. (Lond.) (James McGill Professor) 

Email: qutayba.hamid [at] mcgill.ca (Dr. Qutayba Hamid)
(joint appointment with Medicine)

Profile

Dr. Qutayba Hamid is currently a Professor of Medicine at McGill University, Director of the Meakins-Christie Laboratories, and an Associate Director at the Research Institute of the McGill University Health Center. He holds the prestigious James McGill Chair and clinical Strauss Chair in Respiratory Medicine, and was recently elected to be a fellow of the Royal Society.

Dr. Hamid received his MD from Mosul University, Iraq, and his PhD from the University of London, UK. He has been a professor at McGill University and the Meakins-Christie Laboratories since 1993. In 2004, Dr. Hamid was part of a research team whose landmark study identified a new therapeutic target in controlling asthma, and to date he has published over 450 scientific articles in prominent international journals and has contributed more than 150 chapters and review articles.  He is also the editor of 2 textbooks for Respiratory Cell and Molecular Biology and Respiratory Physiology. Dr. Hamid is also the Co-Editor of the Journal of Clinical and Experimental Allergy and Section Editor for the Journal of Allergy, Asthma, and Clinical Immunology. His research draws millions of dollars in grants from the FRSQ and CIHR on an annual basis and his lab is an important training ground for respiratory professionals in Montreal and continues to attract graduate students and postdoctoral fellows from all over the world.

Research Interests
Dr. Hamid's reserach interests include the pathogenesis of asthma and Chronic Obstructive Pulmonary Disease (COPD), the role of cytokines and chemokines in airway inflammation, and developing new therapies in asthma, allergic rhinitis and COPD.

Recent Publications

The impact of Vitamin D deficiency on asthma, allergic rhinitis and wheezing in children: An emerging public health problem.
Bener A, Ehlayel MS, Bener HZ, Hamid Q.
J Family Community Med. 2014 Sep;21(3):154-61

CXCL1 inhibits airway smooth muscle cell migration through the decoy receptor Duffy antigen receptor for chemokines.
Al-Alwan LA, Chang Y, Rousseau S, Martin JG, Eidelman DH, Hamid Q.
J Immunol. 2014 Aug 1;193(3):1416-26

Aryl hydrocarbon receptor (AhR) attenuation of subchronic cigarette smoke-induced pulmonary neutrophilia is associated with retention of nuclear RelB and suppression of intercellular adhesion molecule-1 (ICAM-1).
de Souza AR, Zago M, Eidelman DH, Hamid Q, Baglole CJ.
Toxicol Sci. 2014 Jul;140(1):204-23.

Vitamin D deficiency and severe asthma.
Poon AH, Mahboub B, Hamid Q.
Pharmacol Ther. 2013 Nov;140(2):148-55.

T helper 17 cells in airway diseases: from laboratory bench to bedside.
Halwani R, Al-Muhsen S, Hamid Q.
Chest. 2013 Feb 1;143(2):494-501

Glucocorticoid receptor-beta up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells.
Vazquez-Tello A, Halwani R, Hamid Q, Al-Muhsen S.
J Clin Immunol. 2013 Feb;33(2):466-78.

Asthma endotypes: the right direction towards personalized medicine for asthma.
Poon AH, Hamid Q.
Expert Rev Clin Immunol. 2012 Sep;8(7):595-6.

Pathogenesis of small airways in asthma.
Hamid Q.
Respiration. 2012;84(1):4-11

Personalized medicine for asthma: Are we there yet?
Poon AH, Hamid Q.
Ann Thorac Med. 2012 Apr;7(2):55-6.

Vitamin D deficiency as a strong predictor of asthma in children.
Bener A, Ehlayel MS, Tulic MK, Hamid Q.
Int Arch Allergy Immunol. 2012;157(2):168-75

398-3864
ex. 00143
398-7483

I. Hüttner; M.D. (Budapest), Ph.D. (McGill) F.R.C.P. (C)

Professor Emeritus (Retired)
Email: eihuttner [at] hotmail.com (Dr. Istvan Hüttner)

Profile

Dr. Istvan Hüttner completed his MD degree with "Summa Cum Laude" at the Semmelweis Medical University, Budapest, Hungary in 1961. He started his career by teaching and pursuing research in vascular pathology in the 2nd Department of Pathology of the same University where he obtained his certificate in Anatomical Pathology and held the title of Assistant Professor. In 1967-68 he obtained a postdoctoral fellowship at the Faculte de Medicine de Paris, France, then in 1969-71 he was awarded a Canadian Arthritis and Rheumatism Society Fellowship at McGill University, Montreal, Canada. While holding this latter fellowship, he started his research that led to original discoveries on vascular endothelium and his prominence in the field of vascular cell biology. He obtained a post-doctoral PhD degree in 1973 at McGill University, certificates in Anatomical Pathology by the American Board of Pathology, the College des Medecins du Quebec and became Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) in 1975. He was appointed to Assistant Professor in 1973, Associate Professor in 1976 and promoted to Full Professor in 1981 at the Department of Pathology, McGill University. He spent a sabbatical year as Visiting Professor at the University of Geneva, Switzerland in 1983-84 where he was also recipient of the Zyma Award.

Until his retirement in 2000 Dr. Hüttner was also a Senior Pathologist at the Royal Victoria Hospital, Montreal. During the first two decades of his tenure at McGill University he excelled primarily in teaching and research and published over 120 scientific papers on the structure and function of vascular endothelium in normal and disease states, particularly cell junction morphology and assembly, including the first description of gap junctions in arterial endothelium, passage of protein tracers through arterial endothelium, cell to cell, and cell to matrix attachments, as well as on phenotypic modulation of vascular smooth muscle cells. He pursued additional research on the sarcolemmal membrane of hereditary and acquired, particularly catecholamine induced cardiac muscle cell alterations. In the last 10 years of his active McGill University/Royal Victoria Hospital position he shifted from a primary research oriented career toward service in diagnostic surgical pathology, an activity that he continued to practice part time for several years after his retirement at various McGill Hospitals, particularly in the Sir Mortimer B. Davies Jewish General Hospital and in the St. Mary's Hospital. As recognition of his many years of meritorious service as Full Professor, McGill University conferred him the honorific title of Professor Emeritus in 2009.

Selected Publications

Gap junctions in arterial endothelium.
Hüttner I, Boutet M, More RH.
J Cell Biol. 1973 Apr;57(1):247-52. No abstract available.

Studies on protein passage through arterial endothelium. I. Structural correlates of permeability in rat arterial endothelium.
Hüttner I, Boutet M, More RH.
Lab Invest. 1973 Jun;28(6):672-7. No abstract available

Studies on protein passage through arterial endothelium. II. Regional differences in permeability to fine structural protein tracers in arterial endothelium of normotensive rat.
Hüttner I, Boutet M, More RH.
Lab Invest. 1973 Jun;28(6):678-85. No abstract available

Studies on protein passage through arterial endothelium. 3. Effect of blood pressure levels on the passage of fine structural protein tracers through rat arterial endothelium.
Hüttner I, Boutet M, Rona G, More RH.
Lab Invest. 1973 Nov;29(5):536-46. No abstract available

Permeability alteration of sarcolemmal membrane in catecholamine-induced cardiac muscle cell injury. In vivo studies with fine structural diffusion tracer horse radish peroxidase.
Boutet M, Hüttner I, Rona G.
Lab Invest. 1976 May;34(5):482-8.

Cytoplasmic filaments and gap junctions in epithelial cells and myofibroblasts during wound healing.
Gabbiani G, Chaponnier C, Hüttner I.
J Cell Biol. 1978 Mar;76(3):561-8.

Heterogeneity of cell junctions in rat aortic endothelium: a freeze-fracture study.
Hüttner I, Peters H.
J Ultrastruct Res. 1978 Sep;64(3):303-8. No abstract available

Opening of tight junctions in cerebral endothelium. I. Effect of hyperosmolar mannitol infused through the internal carotid artery.
Nagy Z, Pappius HM, Mathieson G, Hüttner I.
J Comp Neurol. 1979 Jun 1;185(3):569-78.

Opening of tight junctions in cerebral endothelium. II. Effect of pressure-pulse induced acute arterial hypertension.
Nagy Z, Mathieson G, Hüttner I.
J Comp Neurol. 1979 Jun 1;185(3):579-85

Hüttner , I. The sarcolemma.  In: "Drug-Induced Heart Disease". Ed.:M.A. Birstow, pp. 3-37.  Elsevier/North-Holland biomedical Press, Amsterdam, 1980

Volume, surface, and junctions of rat aortic endothelium during experimental hypertension: a morphometric and freeze fracture study.
Hüttner I, Costabella PM, De Chastonay C, Gabbiani G.
Lab Invest. 1982 May;46(5):489-504.

Vascular endothelium: recent advances and unanswered questions.
Hüttner  I, Gabbiani G.
Lab Invest. 1982 Nov;47(5):409-11. No abstract available

Remodeling of the rat aortic endothelial layer during experimental hypertension. Changes in replication rate, cell density, and surface morphology.
De Chastonay C, Gabbiani G, Elemér G, Hüttner I.
Lab Invest. 1983 Jan;48(1):45-52

Hüttner , I., Gabbiani, G.: Vascular endothelium in hypertension. Chapter 31 in: "Hypertension: Physiopathology and Treatment". Eds.: J.Genest, 0. Kuchel, P. Hamet, M. Cantin, pp.473488. McGraw-Hill, New York, 1983

Numerical densities of intramembrane particles in the cardiac sarcolemma of normal and myopathic Syrian hamsters.
Berry B, Poulsen R, Yunge L, Bruneval P, Fitchett D, de Chastonay C, Gabbiani G, Hüttner I.
J Mol Cell Cardiol. 1983 Aug;15(8):503-13.

Charge-related alterations of the cerebral endothelium.
Nagy Z, Peters H, Hüttner I.
Lab Invest. 1983 Dec;49(6):662-71.

Fracture faces of cell junctions in cerebral endothelium during normal and hyperosmotic conditions.
Nagy Z, Peters H, Hüttner I.
Lab Invest. 1984 Mar;50(3):313-22.

Aortic endothelial cell during regeneration. Remodeling of cell junctions, stress fibers, and stress fiber-membrane attachment domains.
Hüttner I, Walker C, Gabbiani G.
Lab Invest. 1985 Sep;53(3):287-302.

Perturbation of the sarcolemmal membrane in isoproterenol-induced myocardial injury of the rat. Permeability and freeze-fracture studies in vivo and in vitro.
Yunge L, Bruneval P, Cokay MS, Berry B, Peters H, Poulsen R, Hüttner I.
Am J Pathol. 1989 Jan;134(1):171-85.

Hüttner , I., Kocher, O., Gabbiani, G.:  Endothelial and smooth muscle cells. Chapter 1 in: "Diseases of the Arterial Wall". Eds.  J-P. Camilleri, C.L. Berry, J.N. Flessinger, J. Bariety,  pp. 3-41, Springer-Verlag, London, 1989.

Phenotypic features of smooth muscle cells during the evolution of experimental carotid artery intimal thickening. Biochemical and morphologic studies.
Kocher O, Gabbiani F, Gabbiani G, Reidy MA, Cokay MS, Peters H, Hüttner I.
Lab Invest. 1991 Oct;65(4):459-70.

769-8349  

R.P. Michel; B.Sc., M.D., C.M. (McG.), F.R.C.P.(C)

Email: rene.michel [at] mcgill.ca (Dr. Rene P. Michel)

Profile

Education
Dr. Michel obtained his B.Sc. and M.D.,C.M. degrees at McGill University, did two years of residency in Surgery before entering Pathology and obtaining his F.R.C.P. (Path).  His research training was with Dr. James C. Hogg in pulmonary pathophysiology.

He was director of Surgical Pathology from 1988 to 1994, and Chair of the department of Pathology, McGill University and Pathologist-in-chief, Royal Victoria hospital from 1994-1999.  He has been the Director of the Pathology component of Undergraduate medical and dental teaching since 1993, and is also director of Hematopathology and of Transplantation pathology at the McGill University Health center (MUHC).  He has special clinical diagnostic interest in Hematopathology, Transplantation Pathology, and Pulmonary and Hepatic Pathology.

Research Focus
Dr. Michel’s research interests have been in the pulmonary vascular diseases and pulmonary hypertension, pulmonary edema and pulmonary fibrosis, morphometry; clinical research interests are in Hematopathology and Transplantation pathology (hepatic, cardiac, pancreatic, renal).

Selected Publications

Acute respiratory distress syndrome: 30 years later. 
Lesur, O., Berthiaume, Y., Blaise, G., Damas, P., Deland, E., Guimond, J.-G., Michel, R.P.  
Can. Respir. J. 6:71-86, 1999. (Review)

Pretransplantation recipient regulatory T cell suppressive function predicts delayed and slow graft function after kidney transplantation.
Nguyen MT, Fryml E, Sahakian SK, Liu S, Michel RP, Lipman ML, Mucsi I, Cantarovich M, Tchervenkov JI, Paraskevas S.
Transplantation. 2014 Oct 15;98(7):745-53

Hypertonic saline resuscitation of hemorrhagic shock diminishes neutrophil rolling and adherence to endothelium and reduces in vivo vascular leakage.
Pascual JL, Ferri LE, Seely AJ, Campisi G, Chaudhury P, Giannias B, Evans DC, Razek T, Michel RP, Christou NV.
Ann Surg. 2002 Nov;236(5):634-42

Alveolar liquid clearance and sodium channel expression are decreased in transplanted canine lungs.
Sugita M, Ferraro P, Dagenais A, Clermont ME, Barbry P, Michel RP, Berthiaume Y.
Am J Respir Crit Care Med. 2003 May 15;167(10):1440-50

Primary effusion lymphoma: a series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis.
Brimo F, Michel RP, Khetani K, Auger M.
Cancer. 2007 Aug 25;111(4):224-33. Review.

Primary effusion lymphoma involving three body cavities.
Brimo F, Popradi G, Michel RP, Auger M.
Cytojournal. 2009 Oct 9;6:21

Composite cutaneous lymphoma in a patient with rheumatoid arthritis treated with methotrexate.
Huwait H, Wang B, Shustik C, Michel RP.
Am J Dermatopathol. 2010 Feb;32(1):65-70

Induction of pulmonary angiogenesis by adenoviral-mediated gene transfer of vascular endothelial growth factor.
Lambert V, Michel R, Mazmanian GM, Dulmet EM, Capderou A, Hervé P, Planché C, Serraf A.
Ann Thorac Surg. 2004 Feb;77(2):458-63; discussion 463

Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy
Zlobec, I; Vuong, T; Compton, C C; Lugli, A; Michel, R P; et al.
British Journal of Cancer98.2 (Jan 29, 2008): 450-456.


Immunosuppression with budesonide for liver transplant recipients with severe infections.  
Bhat, M., Ghali, P., Wong, P., Marcus, V.,. Michel, R., Cantarovich, M., Metrakos, P., Deschenes, M. 
Liver Transplantation 18:262-3, 2012

Long-term remission after autologous stem-cell transplantation for relapsed histiocytic sarcoma
Abu-Sanad, A., Warsi, A., Michel, R.P., Nahal, A., Popradi, G., Storring, J.M., Liberman, A.S., Alcindor T. 
Curr Oncol, 19:e289-291, 2012.

Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis.
Burnier JV, Wang N, Michel RP, Hassanain M, Li S, Lu Y, Metrakos P, Antecka E, Burnier MN, Ponton A, Gallinger S, Brodt P.
Oncogene. 2011 Sep 1;30(35):3766-83.  

Pulmonary edema. Chapter 19 in “Physiologic Basis of Respiratory Disease”
Michel, R.P., Goldberg, P.
Edited by Q. Hamid, J. Shannon and J. Martin.  BC Decker, Hamilton, ON. 2005, pages 203-236.

934-1934 ex. 38779 934-8296

A. Spatz; MSc., M.D. (Paris)

Email: alan.spatz [at] mcgill.ca (Dr. Alan Spatz)

 

Profile

Dr. Alan Spatz is Director of the Pathology Department at the Jewish General Hospital, and Professor of Pathology and Oncology at McGill University and holds a Canada Research Chair in Molecular Pathology. Dr. Spatz presently directs the X chromosome and Cancer research lab at the Lady Davis Institute and leads an international research group on cutaneous melanoma. He has authored more than 180 original scientific papers, reports, review articles, and books.

Dr. Spatz is also the Director of the McGill-JGH Dubrovsky Molecular Pathology Centre located at the Jewish General Hospital, which opened at the end of 2013. This new cutting-edge facility is leading the way to personalized medicine by using molecular analysis to identify tumour biomarkers to advance the diagnosis and treatment of cancer. 

Research Interests
Dr. Spatz's research is focused on the X chromosome and its role in cancer. His lab is focused on three programs: the regulation and role of FoxP3 gene and its variants, the function of PPP2R3B gene as a metastasis suppressor gene, and the X chromosome-mediated allele specific expression. FoxP3 has a dual role and is both a key player to regulate the immune micro-environment,  and a strong transcription regulator. Dr. Spatz and his team investigate whether its variants have different roles and may have a negative dominant effect. PPP2R3B is one of these fascinating genes that escapes X chromosome inactivation, and is located on the X in females and in the Y in males. In 2004, Dr. Spatz proposed a non-Knudsonian model of X chromosome-based tumor suppressor gene inactivation that then became validated with several genes, including WTX, UPX, and now PPP2R3B. 

Recent Publications

Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy.
Brimo F, Xu B, Scarlata E, Bégin LR, Spatz A, Salomon L, Zakaria AS, Ploussard G, Bladou F, Kassouf W, Tanguay S, Chevalier S, Ye H, Aprikian A.
Hum Pathol. 2014 Oct;45(10):2006-13

From biomarker development towards implementation of multidimensional biomarker panels in a clinical setting.
van Kempen LC, Spatz A.
Mol Oncol. 2014 Jun;8(4):781-2.

Cutaneous melanoma.
Eggermont AM, Spatz A, Robert C.
Lancet. 2014 Mar 1;383(9919):816-27. 

Biopsies: next-generation biospecimens for tailoring therapy.
Basik M, Aguilar-Mahecha A, Rousseau C, Diaz Z, Tejpar S, Spatz A, Greenwood CM, Batist G.
Nat Rev Clin Oncol. 2013 Aug;10(8):437-50.

Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?
Eggermont AM, Spatz A, Lazar V, Robert C.
Curr Opin Oncol. 2012 Mar;24(2):137-40.

Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies.
Batist G, Wu JH, Spatz A, Miller WH Jr, Cocolakis E, Rousseau C, Diaz Z, Ferrario C, Basik M.
Front Pharmacol. 2011 Oct 5;2:59.

Melanoma--the pieces of the puzzle finally start coming together! Preface.
Spatz A, Eggermont AM.
Mol Oncol. 2011 Apr;5(2):113-5.

The dual role of the X-linked FoxP3 gene in human cancers.
Redpath M, Xu B, van Kempen LC, Spatz A.
Mol Oncol. 2011 Apr;5(2):156-63.

340-8222
ex. 5470
340-8102

C.M. Telleria, Ph.D. (University of San Luis Argentina)

Email: carlos.telleria [at] mcgill.ca (Carlos Telleria)

Profile

Dr. Carlos Telleria is a reproductive endocrinologist whose research focuses on understanding the molecular mechanisms driving the physio-pathology of reproductive-related tissues. Dr. Telleria received his doctoral training from the National Council for Scientific and Technical Research (Conicet) of Argentina, and acquired postdoctoral expertise at the Department of Physiology, College of Medicine of the University of Illinois at Chicago. Before joining the Department of Pathology at McGill University, Dr. Telleria navigated the academic ranks at the Division of Biomedical Sciences of the Sanford School of Medicine of the University of South Dakota. During his years as an academic researcher Dr. Telleria mentored several undergraduate and graduate students, and received various awards for research and teaching excellence. Dr. Telleria is currently member of the editorial board of various peer review scientific journals, including Hormones and Cancer, Scientific Reports, Biology of Reproduction, Reproductive Biology and Endocrinology, and Cancer Growth and Metastasis.

Research Interests
The primary research interest in Dr. Telleria’s laboratory is in the field of ovarian cancer biology and preclinical therapy. Ovarian cancer is a deadly disease mostly because is diagnosed when the tumor has already invaded the peritoneal cavity. Diagnosed patients undergo surgery and platinum-based chemotherapy. This standard of care is initially effective, leading to disease remission for about two years in the standard responder. Ultimately, however, the disease recurs and no longer responds to previous therapy. Therefore, novel therapies for ovarian cancer are desperately needed. The overall approach in Dr. Telleria’s lab to develop new potential treatments for this disease is to consider that the time between remission and recurrence can be exploited by using a chronic intervention to maintain residual ovarian cancer cells, which had escaped initial therapy, in a non-proliferative or dormant status, and/or prevent their awakening. Within this scope, current investigations are tailored to understand the pathobiology of ovarian cancer within the microenvironment of the peritoneal cavity, to study the molecular mechanisms driving dormancy of cancer cells that had survived chemotherapy, and to exploit protein homeostasis to develop therapies for non-dividing cancer cells.

Recent Publications

Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors.
Zhang L, Hapon MB, Goyeneche AA, Srinivasan R, Gamarra-Luques CD, Callegari EA, Drappeau DD, Terpstra EJ, Pan B, Knapp JR, Chien J, Wang XJ, Eyster KM, Telleria CM (2016)
Molecular Oncology; 10: 1099-1117.  PMID: 27233943;

Ovarian Cancer Research in the Post Genomic Era: Challenges and Opportunities
Goyeneche AA, Telleria CM (2016)
In: Gynecologic Cancers: Basic Sciences, Clinical, and Therapeutic Perspectives.
Samir Farghaly (Ed.), ISBN: 978-953-51-2254-8; 

Long-term primary culture of a clear cell ovarian carcinoma reveals an epithelial-mesenchymal cooperative interaction.
Goyeneche AA, Koch M, Bell MC, Telleria CM (2015)
Cancer Cell International 15:88. PMID: 26405433;

Antiprogestins in gynecological diseases.
Goyeneche AA, Telleria CM (2015)
Reproduction 149 (1):R15-33. PMID: 25252652

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin- induced cytotoxicity.
Gamarra-Luques CD, Hapon MB, Goyeneche AA, Telleria CM (2014)
Journal of Ovarian Research 7:45. PMID: 24795781

Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells.
Sane S, Abdullah A, Boudreau DA, Autenried RK, Gupta BK, Wang X, Wang H, Schlenker EH, Zhang D, Telleria C, Huang L, Chauhan SC, Rezvani K (2014)
Cell Death and Disease 5: e1118. PMID: 24625977

Repopulation of ovarian cancer cells after chemotherapy.
Telleria CM (2013)
Cancer Growth & Metastasis 6:15-21. PMID: 23544004

Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics.
Brandhagen BN, Tieszen CR, Ulmer TM, Tracy MS, Goyeneche AA, Telleria CM (2013)
BMC Cancer 13:35. PMID: 23351358

Synergistic lethality of mifepristone and  LY294002 in ovarian cancer cells.
Wempe SL, Gamarra-Luques CD, Telleria CM (2013)
Cancer Growth & Metastasis 6:1-13. PMID: 23420486

Drug repurposing for cancer therapy (Editorial).
Telleria CM (2012)
J Cancer Science & Therapy 4.7. PMID: 22984635

Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.
Gamarra-Luques CD, Goyeneche AA, Hapon MB, Telleria CM (2012)
BMC Cancer 112 (1):200. PMID: 22642877

Antiprogestins in Ovarian Cancer, Ovarian Cancer - Clinical and Therapeutic Perspectives, Samir Farghaly (Ed.)
Telleria CM, Goyeneche AA (2012)
ISBN: 978-953-307-810-6

Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDBG-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.
Goyeneche AA, Seidel EE, Telleria CM (2012)
Investigational New Drugs 30: 967-980. PMID: 21424700

Antiprogestin  mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin  regardless of progesterone receptor expression.
Tieszen CR, Goyeneche AA, Brandhagen BN, Ortbahn CT, Telleria CM (2011)
BMC Cancer 11:207. PMID: 21619605

398-5192

398-7446

 

Associate Professors

Name and email

Phone

Fax

L. Alpert; Ph.D., M.D. (Boston)

Email: lesley.alpert [at] gmail.com (Dr. L. Alpert)

340-8222
ex. 4197
340-8102

J. Arseneau; M.D. (Laval), F.R.C.P.(C)

Email: jocelyne.arseneau [at] mcgill.ca (Dr. Jocelyne Arseneau)

934-1934 ex. 38771 934-8296

C. Bernard; M.D. (Sher.)

Email: chantal.bernard [at] muhc.mcgill.ca (Dr. Chantal Bernard)

934-1934
ex. 22220
412-4258

F. Brimo; M.D. (Syria), F.R.C.P.(C)

Email: fadi.brimo [at] mcgill.ca (Dr. Fadi Brimo)

Profile

Clinical Expertise
Dr. Fadi Brimo's is a Staff pathologist at the Montreal General Hospital who specializes in Genito-Urinary Pathology and Cytology.

Research Focus
Morphological, clinical, and basic science studies related to tumors of the Genitourinary tract. The clinical and morphological studies areobservational or outcome-based and address issues impacting diagnostic surgical Pathology, including classification of tumors, original descriptions of histopathologic entities and the development of prognostic biomarkers using tissue microarrays of prostate, bladder and kidney cancer. The basic science work involves collaborations as primary or co-investigator with other McGill clinical departments and research institutions using single nucleotide polymorphism (SNP)-arrays or Fluorescence in situ hybridization (FISH)-assays applied to prostatic and renal carcinoma in the intent of achieving better characterization of the disease at the morphological and prognostic levels. 

Recent Publications

Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA).
W. Kassouf, A. Aprikian, P. Black, G. Kulkarni, J. Izawa, L. Eapen, A. Fairey, A. So, S. North, R. Rendon, S.S. Sridhar, T. Alam, F. Brimo, N. Blais, C. Booth, J. Chin, P. Chung, D. Drachenberg, Y. Fradet, M. Jewett, R.Moore, C. Morash, B. Shayegan, G. Gotto, N. Fleshner, F. Saad, D. R. Siemens.
Can Urol Assoc J. 2016 Feb; 10(1-2): E46-80.   

Neoadjuvant Chemotherapy-Related Histological Changes in Radical Cystectomy: Assessment Accuracy and Prediction of Response
H.Wang, S. Solanki, S. Traboulsi, W. Kassouf, F.Brimo. 
Accepted in Human Pathology.

Fumarate Hydratase-deficient Renal Cell Carcinoma is Strongly Correlated with Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
K.Trpkov, O. Hes, A. Agaimy, M. Bonert, P. Martinek, C. Magi-Galluzzi, G. Kristiansen, C. Lüders, G. Nesi, E. Comperat, M. Sibony, D. M. Berney, R. Mehra, F. Brimo, A. Husain, N. Frizzell, K. Hills, F. Maclean, B. Srinivasan, A. J. Gill. Accepted in the Am J Surg Pathol.

The atypical urothelial cell category in the Paris System: Strengthening the Achilles' heel.
F. Brimo, M. Auger.
Cancer Cytopathol. 2015 Dec 21.

Changes in the expression profiles of claudins during gonocyte differentiation and in seminomas.

G. Manku, A. Hueso, F. Brimo, P. Chan, P. Gonzalez-Peramato, N. Jabado, T. Gayden, M. Bourgey, Y. Riazalhosseini M. Culty.
Andrology. 2016 Jan; 4(1):95-110.

Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study.

L. Florianova, B. Xu, S. Traboulsi, H. Elmansi, S. Tanguay, A. Aprikian, W. Kassouf, F. Brimo.
World J Surg Oncol. 2015 Nov;13:317.

The Molecular Taxonomy of Primary Prostate Cancer.
F. Brimo as part of the Cancer Genome Atlas Research Network Collaboration.
Cell. 2015 Nov 5;163(4):1011-25.

Genitourinary tuberculosis in North America: A rare clinical entity.
MW. Sourial, F. Brimo, R. Horn, S. Andonian.
Can Urol Assoc J. 2015 Jul-Aug;9(7-8)

Cystic clear cell papillary renal cell carcinoma: is it related to multilocular clear cell cystic neoplasm of low malignant potential?
F. Brimo, C. Atallah, G. Li, JR.Srigley.
Histopathology. (Available online, 2015 Aug 7).

Inverted urothelial carcinoma: a series of 12 cases with a wide morphologic spectrum overlapping with the large nested variant.
F. Brimo, S. Dauphin-Pierre, A. Aprikian, W. Kassouf, S. Tanguay, O. Ajise, C. Dongo, LR. Bégin.
Hum Pathol. 2015 Oct;46(10):1506-13.

BCG-related renal granulomas managed conservatively: A case series.
T. Al-Qaoud, F. Brimo, AG. Aprikian, S. Andonian.
Can Urol Assoc J. 2015 Mar-Apr;9(3-4).

Urine cytology: does the number of atypical urothelial cells matter? A qualitative and quantitative study of 112 cases.
F. Brimo, B. Xu, W. Kassouf, B. Khaliji, M. Charbonneau, A. Nahal, Y. Kanber, D. Caglar, M. Auger.
JASC 2015;4(4):232-238

Outcome of repeated prostatic biopsy during active surveillance: implications for focal therapy.
GA Barayan, AG Aprikian, J. Hanley, W. Kassouf, F. Brimo, LR Bégin, S. Tanguay.  
World J Urol. 2015 Sep;33(9):1275-80.

First case of invasive squamous cell carcinoma in a stoma of a Monti ileovesicostomy.
Reid S, Althunayan A, Capolicchio JP, Brimo F, Kassouf W.
Can Urol Assoc J. 2014 Sep;8(9-10):E654-6.

Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy.
Brimo F, Xu B, Scarlata E, Bégin LR, Spatz A, Salomon L, Zakaria AS, Ploussard G, Bladou F, Kassouf W, Tanguay S, Chevalier S, Ye H, Aprikian A.
Hum Pathol. 2014 Oct;45(10):2006-13.

Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.
Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W.
Urol Oncol. 2014 Jul 15. pii: S1078-1439(14)00214-2

The morphologic and immunohistochemical spectrum of papillary renal cell carcinoma: study including 132 cases with pure type 1 and type 2 morphology as well as tumors with overlapping features.
Chevarie-Davis M, Riazalhosseini Y, Arseneault M, Aprikian A, Kassouf W, Tanguay S, Latour M, Brimo F.
Am J Surg Pathol. 2014 Jul;38(7):887-94.

The value of the "suspicious for urothelial carcinoma" cytology category: a correlative study of 4 years including 337 patients.
Ton Nu TN, Kassouf W, Ahmadi-Kaliji B, Charbonneau M, Auger M, Brimo F.
Cancer Cytopathol. 2014 Nov;122(11):796-803.

Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.
Barayan GA, Brimo F, Bégin LR, Hanley JA, Liu Z, Kassouf W, Aprikian AG, Tanguay S.
BJU Int. 2014 Dec;114(6b):E99-E104.

The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature.
Xu B, Chevarie-Davis M, Chevalier S, Scarlata E, Zeizafoun N, Dragomir A, Tanguay S, Kassouf W, Aprikian A, Brimo F.
Hum Pathol. 2014 Mar;45(3):488-97

The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.
Jung S, Wu C, Eslami Z, Tanguay S, Aprikian A, Kassouf W, Brimo F.
Ann Diagn Pathol. 2014 Feb;18(1):27-32.

Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer Biobank.
Brimo F, Aprikian A, Latour M, Têtu B, Doueik A, Scarlata E, Hamel L, McKercher G, Saad F, Lacombe L, Carmel M, Chevalier S.
Biopreserv Biobank. 2013 Oct;11(5):285-90.

Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers.
Chan SW, Nguyen PN,
Cancer Med. 2013 Feb;2(1):63-75.

Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
Xu B, Abourbih S, Sircar K, Kassouf W, Mansure JJ, Aprikian A, Tanguay S, Brimo F.
Arch Pathol Lab Med. 2013 Oct;137(10):1326-36.

Book Chapters
J. Epstein, F. Brimo. “Other Tumors of the Prostate Gland and Tumors of the Seminal Vesicle”, Surgical Pathology of the Genitourinary Tract. Lippincott Williams & Wilkins; Wolters Kluwer Health, First Edition, 2014. Pages 674-709. 

934-1934
ex. 43843
934-8296

S. Camilleri-Broët; M.D. Ph.D. (Paris)

Email: sophie.camilleri-broet [at] muhc.mcgill.ca (Dr. Sophie Camilleri-Broët)

Profile

Dr. Sophie Camilleri-Broët received her MD degree with a specialization in Pathology and her PhD from the medical and scientific University Pierre et Marie Curie (Paris). She then completed a one year research fellowship at the Fred Hutchinson Cancer Research Center (Seattle), and spent three months at the Genome Institute of Singapore as invited scientist. Dr. Camilleri-Broëtwent went on to practice Thoracic Pathology at Hôtel Dieu Hospital in Paris, and GI Pathology at the Hôpital Européen Georges Pompidou.

Research Interests
Dr. Camilleri-Broët’s main clinical areas of expertise are thoracic and GI pathology. She is also interested in translational research and more specifically on genomics and cancer, and has contributed to more than 50 peer-reviewed publications in international journals.

Selected Publications

Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
Tan DS, Camilleri-Broët S, Tan EH, Alifano M, Lim WT, Bobbio A, Zhang S, Ng QS, Ang MK, Iyer NG, Takano A, Lim KH, Régnard JF, Tan P, Broët P.
Int J Cancer. 2014 Sep 1;135(5):1092-100.

Genomic profiles specific to patient ethnicity in lung adenocarcinoma.
Broët P, Dalmasso C, Tan EH, Alifano M, Zhang S, Wu J, Lee MH, Régnard JF, Lim D, Koong HN, Agasthian T, Miller LD, Lim E, Camilleri-Broët S, Tan P.
Clin Cancer Res. 2011 Jun 1;17(11):3542-50

Genomic aberrations in lung adenocarcinoma in never smokers.
Job B, Bernheim A, Beau-Faller M, Camilleri-Broët S, Girard P, Hofman P, Mazières J, Toujani S, Lacroix L, Laffaire J, Dessen P, Fouret P; LG Investigators.
PLoS One. 2010 Dec 6;5(12):e15145.

Neurotensin expression and outcome of malignant pleural mesothelioma.
Alifano M, Loi M, Camilleri-Broet S, Dupouy S, Régnard JF, Forgez P.
Biochimie. 2010 Feb;92(2):164-70.

Finding exclusively deleted or amplified genomic areas in lung adenocarcinomas using a novel chromosomal pattern analysis.
Broët P, Tan P, Alifano M, Camilleri-Broët S, Richardson S.
BMC Med Genomics. 2009 Jul 14;2:43

Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection.
Broët P, Camilleri-Broët S, Zhang S, Alifano M, Bangarusamy D, Battistella M, Wu Y, Tuefferd M, Régnard JF, Lim E, Tan P, Miller LD.
Cancer Res. 2009 Feb 1;69(3):1055-62.

Genome-wide copy number alterations detection in fresh frozen and matched FFPE samples using SNP 6.0 arrays.
Tuefferd M, De Bondt A, Van Den Wyngaert I, Talloen W, Verbeke T, Carvalho B, Clevert DA, Alifano M, Raghavan N, Amaratunga D, Göhlmann H, Broët P, Camilleri-Broët S.
Genes Chromosomes Cancer. 2008 Nov;47(11):957-64.

HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.
Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broët P, Guastalla JP, Allouache D, Combe M, Weber B, Pujade-Lauraine E, Camilleri-Broët S.
PLoS One. 2007 Nov 7;2(11):e1138.

Catamenial and noncatamenial, endometriosis-related or nonendometriosis-related pneumothorax referred for surgery.
Alifano M, Jablonski C, Kadiri H, Falcoz P, Gompel A, Camilleri-Broet S, Regnard JF.
Am J Respir Crit Care Med. 2007 Nov 15;176(10):1048-53.

TRAF4 overexpression is a common characteristic of human carcinomas.
Camilleri-Broët S, Cremer I, Marmey B, Comperat E, Viguié F, Audouin J, Rio MC, Fridman WH, Sautès-Fridman C, Régnier CH.
Oncogene. 2007 Jan 4;26(1):142-7.

A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases.
Camilleri-Broët S, Crinière E, Broët P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphaël M, Iraqi W, Sautès-Fridman C, Colombat P, Hoang-Xuan K, Martin A.
Blood. 2006 Jan 1;107(1):190-6.

Perioperative analysis of biopsies issued from mediastinoscopy.
Alifano M, Charpentier MC, Perrotin C, Molina TJ, Magdeleinat P, Audouin J, Regnard JF, Camilleri-Broët S.
Surg Endosc. 2005 Nov;19(11):1456-9.

Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin.
Compérat E, Zhang F, Perrotin C, Molina T, Magdeleinat P, Marmey B, Régnard JF, Audouin J, Camilleri-Broët S.
Mod Pathol. 2005 Oct;18(10):1371-6.

Peroperative frozen section analysis of TTF-1 antigen expression.
Camilleri-Broet S, Alifano M, Morcos M, Comperat E, Magdeleinat P, Marmey B, Molina TJ, Régnard JF, Audouin J.
J Clin Pathol. 2004 Jan;57(1):98-100.

FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP).
Camilleri-Broët S, Mounier N, Delmer A, Brière J, Casasnovas O, Cassard L, Gaulard P, Christian B, Coiffier B, Sautès-Fridman C.
Leukemia. 2004 Dec;18(12):2038-40.

Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group).
Elie C, Geay JF, Morcos M, Le Tourneau A, Girre V, Broët P, Marmey B, Chauvenet L, Audouin J, Pujade-Lauraine E, Camilleri-Broët S; GINECO Group.
Br J Cancer. 2004 Aug 2;91(3):470-5.

934-1934 ex. 38774 934-8296

B. Case; B.Sc., M.D.,C.M., M.Sc. (McG.) Dipl. Occ. Hyg., F.R.C.P.(C)

Email: bruce.case [at] mcgill.ca (Dr. Bruce Case)

Profile

Dr. Bruce Case is a pathologist and epidemiologist at McGill University in Montreal, Canada. Following his residency in pathology at McGill University he trained with Graham Gibbs and obtained the Diploma in Occupational Hygiene at McGill in 1980, and worked as a post‐doctoral fellow and instructor at the Mount Sinai School of Medicine, New York, from 1980‐83. For this work he was supported by a Fellowship in Occupational Health Research, Conseil de la Recherche en Santé du Québec . While at Mount Sinai Dr. Case performed some of the first studies on asbestos‐mediated free radical release, with the help of the Young Investigator’s Award of the American Lung Association. On his return to McGill he joined with Corbett and Alison McDonald and Patrick Sébastien in the Dust Disease Research Unit: the focus of this group was the epidemiological study of diseases related to mineral fibre exposure using lung‐retained fibre in exposure assessment. In 1986 he received the National Health Scholarship of NHRDP (Canada) for his work in the field.

In 1988 Dr. Case moved to the University of Pittsburgh, where he succeeded Dr. Philip Enterline as Director of the United States Environmental Protection Agency Center for Environmental Epidemiology. He returned to McGill in 1992 and continues research, teaching, and clinical work there in Pathology, Epidemiology, Occupational Health and the McGill School of Environment.

Dr. Case has participated in and given lectures to workshops, and provided peer reviews and advice for many national and international agencies and professional societies on the subject of the exposure assessment and health effects of mineral fibres, including NIOSH, the U.S. Environmental Protection Agency (EPA), and the Centers for Disease Control (CDC, through ATSDR). Dr. Case reviews publications for a wide variety of journals in general medicine, environmental and occupational medicine, industrial hygiene, and risk analysis, including The Lancet, The New England Journal of Medicine, Risk Analysis, Environmental Research, the Canadian Medical Association Journal, Cancer Epidemiology, and Biomarkers, and Prevention.

Dr. Case’s peer‐reviewed research on asbestos and other mineral fibre and particle exposures and related diseases has been funded by American and Canadian public agencies including the Quebec and American Lung Associations, Fonds de Recherche Santé Québec (FRSQ), Institut National de Santé Publique du Québec (INSPQ), American Thoracic Society (USA), the United States Environmental Protection Agency (EPA), MRC/ CIHR (Canada), the National Cancer Institute (of Canada) and the Department of Health and Welfare/Health Canada (Canada). He has published over 140 scientific papers, chapters and abstracts on the results. Dr. Case is also an occasional consultant to North American Regulatory and other Agencies, Workman’s Compensation boards in four Canadian provinces, and to attorneys representing plaintiffs and/or defendants in asbestos litigation. 

Research Interests
Dr. Cases’s main areas of research include asbestos exposure and disease, integration of pathology and epidemiology, mineral fibres and their health effects, mesothelioma, lung cancer, case-control studies, death certification, occupational lung disease, and environmental exposure assessment.

Selected Publications

Many of Dr. Case's publications are available on ResearchGate.

Overreliance on a single study: there is no real evidence that applying quality criteria to exposure in asbestos epidemiology affects the estimated risk.
Berman DW, Case BW.
Ann Occup Hyg. 2012 Oct;56(8):869-78

Pleural mesothelioma surveillance: validity of cases from a tumour registry.
Labrèche F, Case BW, Ostiguy G, Chalaoui J, Camus M, Siemiatycki J.
Can Respir J. 2012 Mar-Apr;19(2):103-7.

Asbestos” to Environmental and “Low-Dose” Exposure Levels and Health Effects, Particularly Malignant Mesothelioma
Case BW, Abraham JL, Meeker G, Pooley FD and Pinkerton
Journal of Toxicology and Environmental Health 2011, Part B, 14: 1, 3 — 39.  

Risk of mesothelioma and occupational exposure to asbestos and man-made vitreous fibers: evidence from two case-control studies in Montreal, Canada.
Pintos J, Parent ME, Case BW, Rousseau MC, Siemiatycki J.
J Occup Environ Med. 2009 Oct;51(10):1177-84.

Heterogeneity of exposure and attribution of mesothelioma: Trends and strategies in two American counties.
Case BW and Abraham JL
J. Phys. 2009 Conf. Ser. 151

Asbestos, smoking, and lung cancer: interaction and attribution.
Case BW.
Occup Environ Med. 2006 Aug;63(8):507-8.

Occupational exposure to asbestos and man-made vitreous fibers, and risk of lung cancer: evidence from two case-control studies in Montreal, Canada.
Pintos J, Parent ME, Rousseau MC, Case BW, Siemiatycki J.
J Occup Environ Med. 2008 Nov;50(11):1273-81.

Correlation of cytotechnologists' parameters with their performance in rapid prescreening of papanicolaou smears.
Djemli A, Khetani K, Case BW, Auger M.
Cancer. 2006 Oct 25;108(5):306-10.

Mineralogical and exposure determinants of pulmonary fibrosis among Québec chrysotile miners and millers.
Nayebzadeh A, Case BW, Massé J, Dufresne A.
Int Arch Occup Environ Health. 2006 Mar;79(3):227-36.

Mesothelioma in Quebec chrysotile miners and millers: epidemiology and aetiology.
McDonald AD, Case BW, Churg A, Dufresne A, Gibbs GW, Sébastien P, McDonald JC.
\
Ann Occup Hyg. 1997 Dec;41(6):707-19.

Asbestos, asbestosis, and lung cancer: observations in Quebec chrysotile workers.
Case BW, Dufresne A.
Environ Health Perspect. 1997 Sep;105 Suppl 5:1113-9.

934-1934
ex. 44398
934-8296

M.F. Chen; M.B., B.S. (Monash), F.R.C.P.(C)

Email: moyfong.chen [at] mcgill.ca (Dr. Moy Fong Chen)

934-1934
ex. 22353
934-8296

M.C. Guiot; B.Sc., M.D. (Bordeaux)

Email: marie.christine.guiot [at] mcgill.ca (Dr. Marie-Christine Guiot)

398-5319 398-5825

T. Haliotis, M.D. (Greece), Ph.D. (Queen's)

Email: tina.haliotis [at] mcgill.ca (Dr. Tina Haliotis)

Profile

Dr. Tina Haliotis is a hematopathologist with a PhD in immunology and experience in basic scientific research in the fields of molecular and cellular oncology.

Research Interests
Dr. Haliotis' current interests lie in the area of translational research in the field of hematological malignancies, particularly lymphomas, with a subspecialty interest in primary cutaneous T-cell lymphoma.

Selected Publications

Gastrointestinal stromal tumor with autonomic nerve differentiation and coexistent mantle cell lymphoma involving the appendix.
Rahimi K, Gologan A, Haliotis T, Lamoureux E, Chetty R.
Int J Clin Exp Pathol. 2008 May 20;2(6):608-13.

Identification and characterization of a transcript for a novel Rac GTPase-activating protein in terminally differentiating 3T3-L1 adipocytes.
Wooltorton EJ, Haliotis T, Mueller CR.
DNA Cell Biol. 1999 Apr;18(4):265-73.

v-Ras and v-Raf block differentiation of transformable C3H10T1/2-derived preadipocytes at lower levels than required for neoplastic transformation.
Raptis L, Brownell HL, Lu Y, Preston T, Narsimhan RP, Anderson S, Schaefer E, Haliotis T.
Exp Cell Res. 1997 Aug 25;235(1):188-97.

Cellular ras gene activity is required for full neoplastic transformation by the large tumor antigen of SV40.
Raptis L, Brownell HL, Corbley MJ, Wood KW, Wang D, Haliotis T.
Cell Growth Differ. 1997 Aug;8(8):891-901.

Ras(leu61) blocks differentiation of transformable 3T3 L1 and C3H10T1/2-derived preadipocytes in a dose- and time-dependent manner.
Raptis L, Yang J, Brownell H, Lai J, Preston T, Corbley MJ, Narsimhan RP, Haliotis T.
Cell Growth Differ. 1997 Jan;8(1):11-21.

340-8222
ex. 5472
340-8102

V. Marcus, M.D., C.M.(McG), F.R.C.P.(C)

Email: victoria.marcus [at] muhc.mcgill.ca (Dr. Victoria Marcus)

934-1934
ex. 43860
934-8296

R. Onerheim; M.D. (Alta.), F.R.C.P.(C)

Email: ronald.onerheim [at] ssss.gouv.qc.ca (Dr. Ronald Onerheim)

345-3511
ex. 3182
734-2743

M. Pelmus; M.D.

Email: mpelmus [at] jgh.mcgill.ca (Dr. Manuela Pelmus)

Profile

Dr. Pelmus has received her MD and PhD degrees from the “Carol Davila” University of Medicine and Pharmacy in Bucharest, Romania. She underwent residency training in Pathology at the same institution, followed by fellowships  training in Bone Pathology and in Soft Tissue Tumors at Cochin Hospital (Paris, France) and Bergonié Institute (Bordeaux, France).  

Since her residency graduation, Dr. Pelmus has been staff pathologist at University Hospital and „Carol Davila” University of Medicine and Pharmacy (Bucharest, Romania),  Sherbrooke University Hospital (Canada) and Jewish General Hospital, Montreal (Canada) with active implication in university teaching programs, research and clinical activity.

Clinical Expertise
Soft Tissue and Bone Pathology
Gynecologic Pathology
Breast Pathology

Research Interests
Triple-negative breast cancers; markers in breast and ovarian neoplasia;  endometrial cancers; pathology of the synovium.

340-8222
4340
340-8102

L. Rochon; M.D. (Sher.), F.R.C.P.(C)

Email: louise.rochon [at] mcgill.ca (Dr. Louise Rochon)

Profile

Dr. Louise Rochon is a Senior Pathologist at the Jewish General Hospital, with expertise in Head and Neck and Thyroid Pathology. At McGill, she is Associate Professor in Pathology and Otorhinolaryngology.

Recent Publications

Ultrasound-guided fine-needle aspiration of thyroid nodules: does size matter?
Varshney R, Forest VI, Zawawi F, Rochon L, Hier MP, Mlynarek A, Tamilia M, Payne RJ.
Am J Otolaryngol. 2014 May-Jun;35(3):373-6.

Intraoperative parathyroid hormone level in parathyroidectomy: which patients benefit from it?
Zawawi F, Mlynarek AM, Cantor A, Varshney R, Black MJ, Hier MP, Rochon L, Payne RJ.
J Otolaryngol Head Neck Surg. 2013 Dec 19;42:56

Lymph node metastasis in thyroid papillary microcarcinoma: a study of 170 patients.
Varshney R, Pakdaman MN, Sands N, Hier MP, Rochon L, Black MJ, Payne RJ.
J Laryngol Otol. 2014 Oct;128(10):922-5.

340-8222
ex. 5474
340-8102

I. Roy; B.Sc.,M.D.,C.M. (McG.), F.R.C.P.(C)

Email: indrojit.roy [at] ssss.gouv.qc.ca (Dr. Indrojit Roy)

345-3511
ex. 3731
734-2743

A.K. Watters; B.Sc., M.D., C.M. (McG), F.R.C.P.(C)

Email: kevin.watters [at] muhc.mcgill.ca (Dr. A.K. Watters)

934-1934
ex. 43840
934-8296

E.A. Zorychta; Ph.D. (McG.)

Email: edith.zorychta [at] mcgill.ca (Dr. E.Zorychta)

398-7125 398-7446


Assistant Professors

Name and email

Phone

Fax

B.  Ahmadi Kaliji, M.D., FRCPC

Email: babak.ahmadikaliji [at] mcgill.ca (Dr. Babak Ahmadi Kaliji)

Profile

Dr Ahmadi Kaliji received his MD degree from the Tehran university of medical sciences in Tehran, Iran. He underwent residency training in Anatomic Pathology at the University of Sherbrooke and McGill university. Dr Ahmadi Kaliji is a fellow of royal college of physicians and surgeons of Canada and a staff pathologist at the Lakeshore general hospital.

Clinical Expertise and Research Interests

Genitourinary pathology, Breast Pathology, Hematopathology, Cytology and Kidney tumors

Selected Publications

 

(514) 630-2225
Ext. 5528

 

O. E. Ajise, M.D., F.C.A.P., F.R.C.P.(C)

Email: oluyomi.ajise [at] muhc.mcgill.ca (Dr. Yomi Ajise)

Profile

Dr. Oluyomi (Yomi) Ajise is a Board certified in Anatomic Pathology in Canada by the Royal College of Physicians and Surgeons of Canada; and in Anatomic Pathology and Clinical Pathology in the United States by the American Board of Pathology. She is a fellow of the Royal College of Physicians and Surgeons of Canada and a fellow of the College of American Pathologists.

Prior to coming to McGill, Dr. Ajise completed two fellowships at the Memorial Sloan-Kettering Cancer Center in New York focusing on (i) Oncologic Surgical Pathology and (ii) Hematopathology; with the latter expected to be completed in June 2014. She received her MD degree from Howard University College of Medicine in Washington, DC in 2005 where she graduated with distinction and was honored as Medical School Valedictorian.  She subsequently completed two years of residency in Internal Medicine at New-York-Presbyterian Hospital/Weill Cornell Medical Center; followed by four years of residency training in Anatomic and Clinical Pathology at New York University in New York, USA.

Clinical Expertise
Dr. Ajise's professional areas of interest include optimum clinical diagnostic services; teaching and clinical research including collaborative research studies.

934-1934
ex. 43839
934-8296

M. Alameldin; M.D., F.R.C.P.(C)

Email: malameldin [at] jgh.mcgill.ca (Dr. Mona Alameldin)

340-8222
ex. 5494
340-8102

S. Albrecht; M.D. (Sher.) F.R.C.P.(C)

Email: steffen.albrecht [at] hotmail.com (Dr. Steffen Albrecht)

398-5325 398-5825

O. Aleynikova; M.D. (Dalhousie), F.R.C.P.(C)

Email: olga.aleynikova [at] mcgill.ca (Dr. Olga Aleynikova)

340-8222
ex. 6744
340-8102

R. Amre; M.B.B.S. (India) F.R.C.P.(C)

Email: ramila.amre [at] muhc.mcgill.ca (Dr. Ramila Amre)

934-1934 ex. 38770 934-8296

K. Bakdounes; M.D. (Syria)

Email: khldoon.bakdounes [at] ssss.gouv.qc.ca (Dr. Khldoun Bakdounes)

Profile

Dr. Khldoun Bakdounes is the Chief pathologist at St Mary Hospital center and Assistant Professor at the department of Pathology, McGill University. He received his MD in 1994 from the Damascus University Damascus, Syria. Dr. Bakdounes pursued his training as a pathologist at State University of New York, combining this with his Masters in Public Health. Thereafter, he finished two fellowships in selective pathology and cytopathology. He was board certified as an anatomical and clinical pathologist in 2006 and cytopathology in 2008. Dr. Bakdounes is a fellow of the Royal College of Physicians of Canada since 2007 and is a Licentiate of the Medical Council of Canada. 

Research Interests
Dr. Bakdounes' main areas of interest are breast pathology, hematopathology and fine needle aspiration cytopathology.

345-3511
ex. 3732
734-2743

M. Blumenkrantz; M.D. (McG)

Email: miriam.blumenkrantz [at] muhc.mcgill.ca (Dr. M. Blumenkrantz)

412-2610 412-4258

G.D. Brandao; M.D. (Brazil)

Email: gbrandao [at] jgh.mcgill.ca (Dr. Guilherme D. Brandao)

340-8222
ex. 2498
340-8102

J. Burnier Ph. D. (McGill)

Julia.burnier [at] mcgill.ca (Email: Dr. Julia Burnier)

 

Profile

After completing a Bachelor of Science Honours degree at Queen’s University, Dr. Burnier pursued a PhD in molecular and cell biology at McGill University (Experimental Medicine). The focus of her PhD was the molecular mechanisms underlying invasion and metastasis. Dr. Burnier went on to become a post-doctoral researcher in clinical research at McGill, where she studied the role of inhibitors of growth in a metastasis model. She then pursued her second postdoctoral fellowship at the Centre for Genomic Regulation (Barcelona, Spain) with a focus on Systems Biology and Proteomics in cancer and later joined IMS as a consultant for the pharmaceutical industry (London, UK). Most recently, Dr. Burnier was a Research Associate in the Department of Medical Oncology, Drug Development Program, at Princess Margaret Hospital (Toronto) where she focused on correlative and translational science in oncology clinical trials. In her academic career, Dr. Burnier has supervised several students and presented her work at numerous international conferences. She has published 18 original articles as well as a book, several book chapters and reviews. She is also a regular reviewer for many prestigious journals and has worked as a freelance science editor, reviewing more than 100 manuscripts for scientists, physicians and industry.

Research Interests and Areas of expertise

Understanding the dynamic molecular changes that occur during tumor progression and metastasis, with a focus on ocular tumors. Identifying tumor markers that can be used to track disease through liquid biopsies.
Expertise: cell biology, genomics, cancer biology, uveal melanoma, metastasis, ophthalmology.

Selected Publications

Eyelid Mycetoma Masquerading as Sebaceous Carcinoma.
Zoroquiain P, Alghamdi S, Arthurs B, Levin L, Sheppard DC, Ralph B, Burnier J, Burnier MN.  Ophthal Plast Reconstr Surg. 2017 May/Jun;33(3S Suppl 1):S101-S104. doi: 10.1097/IOP.0000000000000657.

Analysis of HSP90 Expression Is Valuable in the Differential Diagnosis of Ocular Surface Squamous Lesions
Zoroquiain P, Faingold D, Algahmdi S, Vila N, Logan P, Sanft DM, Toledo Dias AB, Aldrees S, Bravo-Filho V, Burnier J, Burnier MN.  Ophthalmic Res. 2016 Jul;56(2):79-84. doi: 10.1159/000445212. Epub 2016 May 11./aqw007

Pericyte Status in Routinely Discarded Vitrectomy Samples May Be an Early Marker of Diabetic Retinopathy.
Zoroquiain P, Vila N, Bravo-Filho V, Dias AB, Sanft DM, Chen J, Galic J, Kapusta M, Mastromonaco C, Aldrees SS, Burnier J, Burnier MN Jr. Am J Clin Pathol. 2016 Mar;145(3):385-92. doi: 10.1093/ajcp/aqw007.

Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis.
Burnier JV, Wang N, Michel RP, Hassanain M, Li S, Lu Y, Metrakos P, Antecka E, Burnier MN, Ponton A, Gallinger S, Brodt P  Oncogene. 2011 Sep 1;30(35):3766-83. doi: 10.1038/onc.2011.89. Epub 2011 Apr 11.

   

D. Caglar; M.D. (Turkey)

Email: derin.caglar [at] muhc.mcgill.ca (Dr. Derin Caglar)

934-1934
ex. 43837
934-8296


J. Chepovetsky; M.D. (USA)

Email: julie.chepovetsy.COMTL [at] ssss.gouv.qc.ca (Julie Chepovetsky)

345-3511
ex. 3690
734-2743

P. Fiset, MDCM, PhD, FRCPC (McG)

Email:pierre.o.fiset [at] mail.mcgill.ca ( Dr. Pierre Fiset)

   

A. Florea; M.D. (Romania)

Email: anca.florea [at] mcgill.ca (Dr. Anca Florea)

Profile

Dr.Anca Florea received her MD degree from the “Iuliu Hatieganu” University of Medicine and Pharmacy in Cluj-Napoca, Romania. She underwent residency training in Anatomic and Clinical Pathology at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania, USA, followed by a one year fellowship training in Breast and Gynecologic Pathology at the same institution. Since July 2011, Dr. Florea has been an Assistant Professor of Pathology at the McGill University as well as staff pathologist at the Jewish General Hospital in Montreal, Canada. 

Clinical Expertise
Breast Pathology, Gynecologic Pathology, Thyroid Pathology

Research Interests
Dr. Florea's research interests includes the papillary lesions of the breast (especially the encapsulated papillary carcinoma and solid papillary carcinoma) and phyllodes tumors, as well as clear cell carcinoma of the ovary.

340-8222
ex. 5480
340-8102

L. Fu, M.D.,C.M. (McG)

Email: lili.fu [at] muhc.mcgill.ca (Dr. Lili Fu)

934-1934
ex. 43835
934-8296

A. Gologan; M.D. (Romania)

Email: adrian.gologan [at] mcgill.ca (Dr. A. Gologan)

340-8222
ex. 3767
340-8102

A. Gregorieff  B.Sc. ( Université Laval), M.Sc. (McGill University), Ph.D. (Universiteit Utrecht)

Email: Dr.alex.gregorieff [at] mcgill.ca ( )alex.gregorieff [at] mcgill.ca (A Gregorieff)

Profile

My current research interests stem from my doctoral thesis in the lab of Dr. Hans Clevers in the Netherlands. During this time, I studied the Wnt/Tcf pathway and its role in driving intestinal development and homeostasis. Next, I moved to Toronto to pursue my postdoctoral training in the lab of Dr. Jeff Wrana at the Lunenfeld-Tanenbaum Research Institute. Here, I became interested in studying the role of the Hippo signaling effector, Yap, in intestinal stem cells during regeneration and cancer initiation. In 2017, I was appointed assistant professor in the department of pathology at McGill University. My future research goals will be to study the role of the Hippo pathway in stromal cells during gut homeostasis and tumorigenesis. Secondly, I am also interested in dissecting the signals underlying cellular plasticity of adult stem cells. To achieve these goals, I am currently developing a broad range of genetic tools including Cre-lox based mice for gene targeting and lineage tracing experiments, as well as ex vivo organoid culture systems.

Recent Publications

Hippo signalling in intestinal regeneration and cancer
Gregorieff A, Wrana JL
Curr Opin Cell Biol 2017, 48:17-25.

A critical role for NF2 and the Hippo pathway in branching morphogenesis
Reginensi A, Enderle L, Gregorieff A, Johnson RL, Wrana JL, McNeill H
Nat Commun 2016, 7:12309.

YAP and TAZ control peripheral myelination and the expression of laminin receptors in Schwann cells
Poitelon Y, Lopez-Anido C, Catignas K, Berti C, Palmisano M, Williamson C, Ameroso D, Abiko K, Hwang Y, Gregorieff A, et al.
Nat Neurosci 2016, 19:879-887

Seeing is believing: Wnt3 localization in the gut epithelium
Gregorieff A, Wrana JL
Cell Res 2016, 26:515-516

Multiple roles for the hippo effector yap in gut regeneration and cancer initiation
Gregorieff A, Wrana JL
Mol Cell Oncol 2016, 3:e1143992

YB-1 is elevated in medulloblastoma and drives proliferation in Sonic hedgehog-dependent cerebellar granule neuron progenitor cells and medulloblastoma cells
Dey A, Robitaille M, Remke M, Maier C, Malhotra A, Gregorieff A, Wrana JL, Taylor MD, Angers S, Kenney AM
Oncogene 2016,35:4256-4268.

Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer
Gregorieff A, Liu Y, Inanlou MR, Khomchuk Y, Wrana JL
Nature 2015, 526:715-718

934-1934
ex. 76137

 

S.Jung; M.D. (Korea)

Email: sung-mi.jung [at] muhc.mcgill.ca (Dr. Sungmi Jung)

934-1934
ex. 43842
934-8296

Y. Kanber; M.D. (Turkey)

Email: yonca.kanber [at] muhc.mcgill.ca (Dr. Yonca Kanber)

934-1934 ex. 62610 934-8296

J. Karamchandani; M.D. (Stanford)

Email: jason.karamchandani [at] mcgill.ca (Dr. Jason Karamchandani)

Profile

Dr. Jason Karamchandani graduated from Harvard College and attended medical school at Stanford University School of Medicine, where he remained for his residency training in anatomic  pathology. He followed up with fellowship training in surgical pathology and neuropathology. Dr. Karamchandani went on to practice neuropathology at St. Michael’s Hospital in Toronto, where he served as the director of the immunopathology laboratory. 

Research Focus
Dr. Karamchandani’s research is focused on tumors of the central nervous system and peripheral nerves with a focus on molecular pathology, bioinformatics, and the identification and characterization of diagnostic and prognostic biomarkers. 

Recent Publications

Emphysematous esophagitis associated with Sarcina organisms in a patient receiving anti-inflammatory therapy.
Carrigan S, Grin A, Al-Haddad S, Iakovlev V, Streutker C, Moore T, Karamchandani J.
Histopathology. 2014 Nov 19

Chordoid meningiomas: Incidence and clinicopathological features of a case series over 18 years.
Di Ieva A, Laiq S, Nejad R, Schmitz EM, Fathalla H, Karamchandani J, Munoz DG, Cusimano MD.
Neuropathology. 2014 Nov 6.

Chordoid meningiomas: Incidence and clinicopathological features of a case series over 18 years.
Di Ieva A, Laiq S, Nejad R, Schmitz EM, Fathalla H, Karamchandani J, Munoz DG, Cusimano MD.
Neuropathology. 2014 Nov 6.

Sox10 is Superior to S100 in the Diagnosis of Meningioma.
Ng J, Celebre A, Munoz DG, Keith JL, Karamchandani JR.
Appl Immunohistochem Mol Morphol. 2014 Sep 26. 

IDH mutation in glioma: new insights and promises for the future.
Turkalp Z, Karamchandani J, Das S.
JAMA Neurol. 2014 Oct;71(10):1319-25.

Co-occurrence of a cerebral cavernous malformation and an orbital cavernous hemangioma in a patient with seizures and visual symptoms: Rare crossroads for vascular malformations.
Choudhri O, Feroze AH, Lad EM, Kim JW, Plowey ED, Karamchandani JR, Chang SD.
Surg Neurol Int. 2014 Jun 19;5(Suppl 4):S148-54.

Ectopic prolactin-producing pituitary adenoma in a benign ovarian cystic teratoma.
Al-Bazzaz S, Karamchandani J, Mocarski E, Horvath E, Rotondo F, Kovacs K.
Endocr Pathol. 2014 Sep;25(3):321-3

Mouse models of glioblastoma: lessons learned and questions to be answered.
Janbazian L, Karamchandani J, Das S.
J Neurooncol. 2014 May;118(1):1-8.

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats.
Walters MJ, Ebsworth K, Berahovich RD, Penfold ME, Liu SC, Al Omran R, Kioi M, Chernikova SB, Tseng D, Mulkearns-Hubert EE, Sinyuk M, Ransohoff RM, Lathia JD, Karamchandani J, Kohrt HE, Zhang P, Powers JP, Jaen JC, Schall TJ, Merchant M, Recht L, Brown JM.
Br J Cancer. 2014 Mar 4;110(5):1179-88

Flexible omnidirectional carbon dioxide laser as an effective tool for resection of brainstem, supratentorial, and intramedullary cavernous malformations.
Choudhri O, Karamchandani J, Gooderham P, Steinberg GK.
Neurosurgery. 2014 Mar;10 Suppl 1:34-4; discussion 43-5.

398-5348 398-5825

J. Lavoie; M.D., Ph.D. (Laval)

Email: jlavoie [at] muihc.mcgill.ca (Dr. )jlavoie [at] muihc.mcgill.ca (Josée)jlavoie [at] muihc.mcgill.ca ( Lavoie)

Recent Publications

VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer.
Gambaro K, Quinn MC, Wojnarowicz PM, Arcand SL, de Ladurantaye M, Barrès V, Ripeau JS, Killary AM, Davis EC, Lavoie J, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN.
Mol Oncol. 2013 Jun;7(3):513-30.

Canadian College of Medical Geneticists guidelines for the indications, analysis, and reporting of cancer specimens.
Dawson AJ, McGowan-Jordan J, Chernos J, Xu J, Lavoie J, Wang JC, Steinraths M, Shetty S.
Curr Oncol. 2011 Oct;18(5):e250-5.

CCMG guidelines: prenatal and postnatal diagnostic testing for uniparental disomy.
Dawson AJ, Chernos J, McGowan-Jordan J, Lavoie J, Shetty S, Steinraths M, Wang JC, Xu J; Canadian College of Medical Geneticists committees.
Clin Genet. 2011 Feb;79(2):118-24.

Blood transfusion risks and alternative strategies in pediatric patients.
Lavoie J.
Paediatr Anaesth. 2011 Jan;21(1):14-24.

Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia.
Rio Frio T, Lavoie J, Hamel N, Geyer FC, Kushner YB, Novak DJ, Wark L, Capelli C, Reis-Filho JS, Mai S, Pastinen T, Tischkowitz MD, Marcus VA, Foulkes WD.
N Engl J Med. 2010 Dec 30;363(27):2628-37.

Locus-specific dual color-probe for the enumeration of chromosome 18 in rapid FISH aneuploidy testing on uncultured amniocytes.
Soucy JF, Lavoie J, Duncan AM.
Prenat Diagn. 2010 Aug;30(8):811-2.

Epigenetic modification of the gene for the vitamin B(12) chaperone MMACHC can result in increased tumorigenicity and methionine dependence.
Loewy AD, Niles KM, Anastasio N, Watkins D, Lavoie J, Lerner-Ellis JP, Pastinen T, Trasler JM, Rosenblatt DS.
Mol Genet Metab. 2009 Apr;96(4):261-7.

934-1934
ex. 23544
412-3544

H.R.Lopez-Valle;M.D. (Mexico)

Email: hilda-ruth.lopez-valle [at] ssss.gouv.qc.ca (Dr. Hilda Ruth Lopez-Valle)

345-3511
ex. 3734
734-2743

A.T. Marcus; B.Sc., M.D., C.M. (McG), F.R.C.P.(C)

Email: alexander.marcus [at] ssss.gouv.qc.ca (Dr. Alexander T. Marcus)

345-3511
ex. 3456
734-2743

V.-H. Nguyen; M.D. (Montr.), F.R.C.P.(C)

van-hung.nguyen [at] muhc.mcgill.ca (Email: Dr Van-Hung Nguyen)

934-1934
ex. 22198
412-4258

Tuyet Nhung Ton Nu MD, FRCPC

Email: tuyet.tonnu [at] mcgill.ca (Dr. Ton Nu)

934-1934 Ext. 143786

934-8437

A. Omeroglu, M.D. (Turkey)

Email: atilla.omeroglu [at] muhc.mcgill.ca (Dr. Atilla Omeroglu)

934-1934 ex. 62266 934-8296

G. Omeroglu-Altinel, M.D. (Turkey)

Email: gulbeyaz.omeroglu-altinel [at] muhc.mcgill.ca (Dr. Gulbeyaz Omeroglu-Altinel)

934-1934 ex. 62233

934-8296

F. Razaghi, M.D. (Iran)

Email: farshid.razaghi.chsm [at] ssss.gouv.qc.ca (Dr. Farshid Razaghi)

Profile

Dr. Razaghi received his MD from the “Beheshti” University of Medical science in Tehran, Iran. He underwent residency training in Pathology at McGill University, followed by fellowship training in Cytology at Dartmouth-Hitchcock Medical Center in New Hampshire, USA.

Dr. Razaghi is a staff pathologist at St-Mary's Hospital and actively participates in the teaching of medical students and residents.

Clinical Expertise
Cytology, Soft Tissue and Bone Pathology, Dermatopathology and Gastrointestinal pathology

345 3511 ex. 3731 734 2743

S. Sabri; Ph.D. (Paris)

Email: siham.sabri [at] mcgill.ca (Dr. Siham Sabri)

Profile

Dr. Siham Sabri is an Assistant Professor in the Department of Oncology (Division of Radiation Oncology, appointed since August 1st, 2011) and principle investigator at the Research Institute of the MUHC. Dr. Sabri joined the Department of Pathology as an associate member in 2013. 

Research Interests
Dr. Sabri is currently investigating the molecular mechanisms of tumor angiogenesis and invasion in glioblastoma multiforme within a large translational research project with a pre-clinical in vivo study and an ongoing clinical trial. In addition, her research interests encompass the molecular mechanisms of radiation-induced lung fibrosis (in collaboration with Dr Qutayba Hamid, the Director of Meakins-Christie Laboratories and other investigators from this center).

 

Selected Publications

Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
Lesniak D, Sabri S, Xu Y, Graham K, Bhatnagar P, Suresh M, Abdulkarim B.
PLoS One. 2013 Aug 26;8(8):e71987.

O6-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme.
Chahal M, Abdulkarim B, Xu Y, Guiot MC, Easaw JC, Stifani N, Sabri S.
Mol Cancer Ther. 2012 Nov;11(11):2440-50.

Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.
Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S.
J Clin Oncol. 2011 Jul 20;29(21):2852-8.

The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
Gabos Z, Thoms J, Ghosh S, Hanson J, Deschênes J, Sabri S, Abdulkarim B.
Breast Cancer Res Treat. 2010 Nov;124(1):187-94.

MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M, Jacques A, Murray D, Sabri S, Abdulkarim B.
Neuro Oncol. 2010 Aug;12(8):822-33.

934-1934
Ex. 44686
 

S. Sandhu;M.B.B.S. (India)

Email: sangeeta.sandhu [at] ssss.gouv.qc.ca (Dr. Sangeeta Sandhu)

Profile

Dr. Sangeeta Sandhu earned her Medical Degree (M.B.B.S.) from North Bengal Medical College, Sushrutanagar, India in 1990. She obtained a Prosectorship in Biochemistry and topped her final MBBS in Surgery to prove that she had a keen analytic mind and the cutting edge. After completing her internship in a rural based setting she went on to do an obligatory year of residency in Obstetrics and Gynecology at the Post Graduate Institute, Kolkata, West Bengal. As she started her second year of residency in Radiation Oncology, she was drawn towards the diagnostic aspect of disease progression and felt she could better serve humanity by placing herself at the critical junction between prevention and cure. She completed her post graduate training and became board certified in Combined Anatomic and Clinical Pathology from St. Luke’s-Roosevelt Hospital Center, Columbia University, New York city. This was followed by a fellowship in Surgical Oncologic Pathology, at the University of Illinois, Chicago and a second fellowship in Hematopathology at the Albert Einstein College of Medicine, New York. She trained in Molecular Diagnostics at the National Institute of Health, Bethesda with Drs. Elaine Jaffe and Mark Raffeld.

Dr. Sandhu now practices at St. Mary’s Hospital Center, a community based center affiliated with McGill University, Montreal. She has the satisfaction of upholding the four pillars of Medicine - Clinical, Education, Research and Administration. 

345-3511
ex. 3690
734-2743

H. Srolovitz; B.Sc. (Pitt), M.D. (Basie)

Email: hsrolovi [at] pat.jgh.mcgill.ca (Dr. Herbert Srolovitz)

340-8222
ex. 5473
340-8102

J. St. Cyr; M.D.,C.M. (McG.), F.R.C.P.(C)

Email: julie.st-cyr [at] ssss.gouv.qc.ca (Dr. Julie St-Cyr)

345-3511
ex. 3076
734-2743

H. Wang; M.D. (China)

Email: hangjunwang [at] jgh.mcgill.ca (Dr. Hangjun Wang)

340-8222
ex. 5470
340-8102

Visiting Professors

Abu Shadat Mohammod Noman Ph.D. (Aichi)                                                                                                                            

Email: abu.noman [at] mcgill.ca (A.S.M. Noman)

Profile

Dr. Abu Shadat Mohammod Noman  received his BSc and MSc from University of Rajshahi, Bangladesh and PhD from Aichi Medical University, Japan. He then accomplished several Postdoctoral fellowships at University of Massachusetts Medical School, and Hollings Cancer Center with a collaborative experience in Harvard Stem Cell Institute. Dr. Noman   continued his early research career as an Assistant Professor   in the Department of Biochemistry & Molecular Biology, University of Chittagong, Bangladesh in 2011, then as Associate Professor since 2012. He has recently joined the Department of Pathology at McGill University as Visiting Professor.
Dr. Noman has made a major impact in Tumor Immunology by his original research work in the last decade. His research program has contributed to elucidating the role of critical inflammation and cancer regulators with the overarching goal to design therapeutic strategies. He has identified the novel role of retinoblastoma protein-interacting zinc finger 1 (RIZ1) in Toll Like Receptor (TLR)4 network (Cell Immunol, 2010; Immunol Lett, 2010; Cancer Investigation, 2010) and identified novel inhibitors including peptide inhibitor of endotoxin responsiveness (PIER) to block TLR4 functions (JBC, 2012; Innate Immun, 2009).
His group has focused on triple negative breast cancer (TNBC) to introduce an effective therapeutic approach. To date designing a treatment plan for patients diagnosed with TNBC is challenging with the poorest survival prognosis among other molecular subtypes of breast cancer. Dr. Noman established for the first time the role of sonic hedgehog (Shh) in TNBC progression and described its association with tumor regulatory cytokines (Sci Rep, 2016, & 2017). He showed the correlation of Shh and IL-6 overexpression with aggressive phenotype  and poorer overall survival of TNBC which paves the way to Shh- based  diagnostic and therapeutic strategy for TNBC. His contribution to science is highly recognized by several prestigious awards including TWAS (The World Academy of Science) Prize with Bangladesh Academy of Science (BAS) Award.

Research Interests

Dr. Noman is intending to map complete networks of genetic and molecular interactions to decode the mechanisms of immune suppression in cancer, and how the changing of these networks propagate tumorigenesis in patients. Currently, he focuses on exploring a novel immunotherapeutic strategy for a specific sub-group of Glioblastoma multiforme (GBM) patients. His primary interest is to understand the genomic landscape and other networks to identify potent immune regulators, tumor-specific antigens and neoepitopes directly from the patients. To achieve this aim, in collaboration with the group of Dr. Sabri (Department of Pathology), Dr. Noman is utilizing high throughput analysis of expression profile of immune genes and validation of their networks during tumor progression at recurrence with the goal to identify novel therapeutic targets and develop diagnostic tools for GBM.
Alongside, Dr. Noman is stepping towards a multidisciplinary and interdisciplinary translational research effort with the goal to develop novel molecular targets in TNBC and new therapies in combination with conventional therapies, as part of an immuno-oncology research effort.

Selected  Publications

Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer.
Noman AS, Uddin M, Chowdhury AA, Nayeem MJ, Raihan Z, Rashid MI, Azad AK, Rahman ML, Barua D, Sultana A, Shirin A, Ferdous J, Parag RR, Rahman SM, Mahmud MR, Jerin CS, Jahan N, Siddiqua A, Ara T, Sabur EB, Alam SS, Baidya S, Akther S, Rahman MZ, Banu T, Murugan AK, Sabri S, Islam SMS, Karakas B, Aboussekhra A, Yeger H, Farhat WA, Islam SS.
Sci Rep. 2017 May 11; 7(1):1796. PMID: 28496132

Overexpression of sonic hedgehog in the triple negative breast cancer: clinicopathological characteristics of high burden breast cancer patients from Bangladesh.
Noman AS, Uddin M, Rahman MZ, Nayeem MJ, Alam SS, Khatun Z, Wahiduzzaman M, Sultana A, Rahman ML, Ali MY, Barua D, Ahmed I, Islam MS, Aboussekhra A, Yeger H, Farhat WA, Islam SS.
Sci Rep. 2016 Jan 5; 6:18830. PMID: 26727947

Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer.
Islam SS, Mokhtari RB, Noman AS, Uddin M, Rahman MZ, Azadi MA, Zlotta A, van der Kwast T, Yeger H, Farhat WA.
Mol Carcinog. 2016 May;55(5):537-51. PMID: 25728352

Chaperone gp96-independent inhibition of endotoxin response by chaperone-based peptide inhibitors.
Wu S, Dole K, Hong F, Noman AS, Issacs J, Liu B, Li Z.
J Biol Chem. 2012 Jun; 287(24):19896-903. PMID: 22532561

Retinoblastoma protein-interacting zinc finger 1, a tumor suppressor, augments lipopolysaccharide-induced proinflammatory cytokine production via enhancing nuclear factor-kappaB activation.
Noman AS, Koide N, Iftakhar-E-Khuda I, Dagvadorj J, Tumurkhuu G, Naiki Y, Komatsu T, Yoshida T, Yokochi T.
Cell Immunol. 2010 May;264(2):114-8. PMID: 20557878

Retinoblastoma protein-interacting zinc finger 1 (RIZ1) participates in RANKL-induced osteoclast formation via regulation of NFATc1 expression.
Noman AS, Koide N, Iftakhar-E-Khuda I, Dagvadorj J, Tumurkhuu G, Naiki Y, Komatsu T, Yoshida T, Yokochi T.
Immunol Lett. 2010 Jul 8;131(2):166-9. PMID:20417662

Retinoblastoma protein-interacting zinc finger 1 (RIZ1) regulates the proliferation of monocytic leukemia cells via activation of p53.
Shadat NM, Koide N, Khuda II, Dagvadorj J, Tumurkhuu G, Naiki Y, Komatsu T, Yoshida T, Yokochi T.
Cancer Invest. 2010 Oct;28(8):806-12. PMID: 20594067

Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression.
Noman AS, Koide N, Hassan F, I-E-Khuda I, Dagvadorj J, Tumurkhuu G, Islam S, Naiki Y, Yoshida T, Yokochi T.
Innate Immun. 2009 Feb;15(1):33-41. PMID: 19201823

Thalidomide inhibits epidermal growth factor-induced cell growth in mouse and human monocytic leukemia cells via Ras inactivation.
Noman AS, Koide N, Khuda II, Dagvadorj J, Tumurkhuu G, Naiki Y, Komatsu T, Yoshida T, Yokochi T.
Biochem Biophys Res Commun. 2008 Oct 3;374(4):683-7. PMID: 18662673

398-5324  

Associate Members

Name and email

Phone

Fax

B. S. Abdulkarim; M.D., Ph.D., (Paris) F.R.C.P.(C)

Email: bassam.abdulkarim [at] mcgill.ca (Dr. Bassam Abdulkarim)

Profile

Dr. Bassam Abdulkarim is an Associate Professor in the Department of Oncology (Director, Division of Radiation Oncology, since April, 2011) and principle investigator at the Research Institute of the MUHC. Dr. Abdulkarim joined the Department of Pathology as an associate member in 2013.

Research Interests
Dr. Abdulkarim’s main research focus is on translational research in Lung cancer and Brain tumor. His is currently investigating the effect of different types of radiation fractionation including ablative dose of radiation in lung cancer and brain tumor.

Dr. Abdulkarim’s major interest is to develop prognostic and predictive biomarkers to radiation alone or in combination with new-targeted therapies. In addition, one of his research interests is focusing on the “comprehensive approach of lung cancer, radiation-induced fibrosis, and development of new therapeutics. 

Recent Publications

YB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells.
Jung K, Wu F, Wang P, Ye X, Abdulkarim BS, Lai R.
BMC Cancer. 2014 May 9;14:328.

Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays.
Jung K, Wang P, Gupta N, Gopal K, Wu F, Ye X, Alshareef A, Bigras G, McMullen TP, Abdulkarim BS, Lai R.
Breast Cancer Res. 2014 Nov 8;16(6):470.

A Phase I Study of Tomotherapy in Patients With Primary Benign and Low-grade Brain Tumors: Late Toxicity and Quality of Life.
Boychak A, Bauman G, Fisher B, Abdulkarim B, Amanie J, Fulton D, Murtha A, Patel S, Urtasun R, Ghosh S, Roa WH.
Am J Clin Oncol. 2014 Jan 22.

Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
Lesniak D, Sabri S, Xu Y, Graham K, Bhatnagar P, Suresh M, Abdulkarim B.
PLoS One. 2013 Aug 26;8(8):e71987.

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.
Radiat Oncol. 2013 Feb 20;8:38.

O6-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme.
Chahal M, Abdulkarim B, Xu Y, Guiot MC, Easaw JC, Stifani N, Sabri S.
Mol Cancer Ther. 2012 Nov;11(11):2440-50.

934-1934
ex. 43594
934-8392

C.J. Baglole; Ph.D. (University of Calgary)

Email: carolyn.baglole [at] mcgill.ca (Dr. Carolyn Baglole)

Profile

Dr. Baglole received her BSc and MSc from the University of Prince Edward Island, and her PhD from the University of Calgary. She then did postdoctoral research and subsequently joined the academic staff at the University of Rochester, before returning to Canada where she is currently an Assistant Professor in the Department of Medicine and an Associate Member in the Department of Pathology at McGill.

Research Interests: The research in her laboratory is aimed at identifying novel intracellular and molecular pathways that control the pathogenesis of chronic lung diseases associated with environmental exposures, particularly cigarette smoke. Her main focus is understanding how cigarette smoke-induced inflammation and cell death (apoptosis) are regulated. Chronic and persistent inflammation and the death of lung cells are involved in the etiology of lung diseases such as chronic obstructive pulmonary disease (COPD), which is almost always caused by cigarette smoke (>90% of cases).  There is no cure for individuals afflicted with COPD and there are no effective therapies that can reduce disease progression. This is due, in part, to a lack of novel intracellular targets for the development of pharmacological therapies.

In this regard, her lab was the first to publish that the mere presence of a cellular receptor called the aryl hydrocarbon receptor (AhR) attenuates lung inflammation caused by cigarette smoke. This was a novel finding, as the normal physiological function of this receptor, which is best known for its ability to respond to synthetic toxicants, had not previously been described. Beyond its regulation of inflammation in the lung caused by cigarette smoke, they also investigate the role of the AhR in attenuating apoptosis, a feature that is characteristic of lung tissue destruction in COPD. Using genetic, molecular  and biochemical approaches, together with in vitro and in vivo models of smoke exposure, her research is focused on establishing that the AhR is a novel and important regulator of apoptosis and understanding in vivo, and the role of the AhR in preventing morphological features of emphysema in the lung.

Recent Publications

The NF-κB Family Member RelB Attenuates Cigarette Smoke Extract-induced Apoptosis in Lung Fibroblasts via Transcriptional Regulation of the Aryl Hydrocarbon Receptor
Iu M, Zago M, Rico de Souza A, Bouttier M, White JH, Hamid Q, Eidelman DH and Baglole CJ.
Free Rad Biol Med.  Accepted, 2017.

Inhaled Pollutants: The Molecular Scene behind Respiratory and Systemic Diseases Associated with Ultrafine Particulate Matter
Traboulsi H, Guerrina N, Iu M, Maysinger D, Ariya P, Baglole CJ
Int J Mol Sci. 2017 Jan 24;18(2). pii: E243. doi: 10.3390/ijms18020243. Review.

Aryl hydrocarbon receptor (AhR)-dependent regulation of pulmonary miRNA by chronic cigarette smoke exposure
Rogers S, de Souza AR, Zago M, Iu M, Guerrina N, Gomez A, Matthews J, Baglole CJ.
Sci Rep. 2017 Jan 12;7:40539. doi: 10.1038/srep40539

Monocyte-derived fibrocytes induce an inflammatory phenotype in airway smooth muscle cells.
Lin TY, Venkatesan N, Nishioka M, Kyoh S, Al-Alwan L, Baglole CJ, Eidelman DH, Ludwig MS, Hamid Q.
Clin Exp Allergy. 2014 Nov;44(11):1347-60

Alterations in the expression of the NF-κB family member RelB as a novel marker of cardiovascular outcomes during acute exacerbations of chronic obstructive pulmonary disease.
Labonté L, Coulombe P, Zago M, Bourbeau J, Baglole CJ.
PLoS One. 2014 Nov 19;9(11):e112965.

Aryl hydrocarbon receptor-dependent regulation of miR-196a expression controls lung fibroblast apoptosis but not proliferation.
Hecht E, Zago M, Sarill M, Rico de Souza A, Gomez A, Matthews J, Hamid Q, Eidelman DH, Baglole CJ.
Toxicol Appl Pharmacol. 2014 Nov 1;280(3):511-25

Aryl hydrocarbon receptor (AhR) attenuation of subchronic cigarette smoke-induced pulmonary neutrophilia is associated with retention of
nuclear RelB and suppression of intercellular adhesion molecule-1 (ICAM-1).

de Souza AR, Zago M, Eidelman DH, Hamid Q, Baglole CJ
.
Toxicol Sci. 2014 Jul;140(1):204-23

The NF-κB family member RelB regulates microRNA miR-146a to suppress cigarette smoke-induced COX-2 protein expression in lung fibroblasts.
Zago M, Rico de Souza A, Hecht E, Rousseau S, Hamid Q, Eidelman DH, Baglole CJ
.
Toxicol Lett. 2014 Apr 21;226(2):107-16

Genetic deletion of IL-17A reduces cigarette smoke-induced inflammation and alveolar type II cell apoptosis.
Chang Y, Al-Alwan L, Audusseau S, Chouiali F, Carlevaro-Fita J, Iwakura Y, Baglole CJ
, Eidelman DH, Hamid Q.
Am J Physiol Lung Cell Mol Physiol. 2014 Jan;306(2):L132-43.

Aryl hydrocarbon receptor-dependent retention of nuclear HuR suppresses cigarette smoke-induced cyclooxygenase-2 expression independent of DNA-binding.
Zago M, Sheridan JA, Nair P, Rico de Souza A, Gallouzi IE, Rousseau S, Di Marco S, Hamid Q, Eidelman DH, Baglole CJ
.
PLoS One. 2013 Sep 27;8(9):e74953.

Differential roles of CXCL2 and CXCL3 and their receptors in regulating normal and asthmatic airway smooth muscle cell migration.
Al-Alwan LA, Chang Y, Mogas A, Halayko AJ, Baglole CJ
, Martin JG, Rousseau S, Eidelman DH, Hamid Q.
J Immunol. 2013 Sep 1;191(5):2731-41.

IL-8 production in response to cigarette smoke is decreased in epithelial cells from COPD patients.
Nadigel J, Audusseau S, Baglole CJ
, Eidelman DH, Hamid Q.
Pulm Pharmacol Ther. 2013 Oct;26(5):596-602.

398-3864
ex. 00277
398-7483

P.J. Chauvin; M.Sc. (W.Ont.), D.D.S. (McG.)

Email: peter.chauvin [at] muhc.mcgill.ca (Dr. Peter J. Chauvin)

934-1934
ex. 43844
934-8296

M. Divangahi; Ph.D. (McG)

Email: maziar.divangahi [at] mcgill.ca (Dr. Maziar Divangahi)

Profile

Dr. Maziar Divangahi completed his PhD in the Department of Medicine at McGill University in 2005. He went to pursue three fellowships in Molecular Immunology and Infectious Diseases at McMaster University, McGill and Harvard University before being appointed at McGill as an Assistant Professor in the departments of Medicine and Microbiology & Immunology. He joined the Department of Pathology as an associate member in 2012. 

Research Interests
Dr. Divangahi's research focuses on investigating the cellular and molecular mechanisms involved in cross-talk between innate and adaptive immunity to major pulmonary infectious diseases such as influenza and tuberculosis. He believes that understanding the different arms of immunity are essential for the future development of an effective therapy or vaccine.

Publications

Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection.
Tzelepis F, Verway M, Daoud J, Gillard J, Hassani-Ardakani K, Dunn J, Downey J, Gentile ME, Jaworska J, Sanchez AM, Nédélec Y, Vali H, Tabrizian M, Kristof AS, King IL, Barreiro LB, Divangahi M.
J Clin Invest. 2014 Dec 22. pii: 77014.

Toll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophy.
Giordano C, Mojumdar K, Liang F, Lemaire C, Li T, Richardson J, Divangahi M, Qureshi S, Petrof BJ.
Hum Mol Genet. 2014 Dec 30. pii: ddu735.

Freund's adjuvant, NOD2 and mycobacteria.
Behr MA, Divangahi M.
Curr Opin Microbiol. 2014 Dec 5;23C:126-132.

Targeting eicosanoid pathways in the development of novel anti-influenza drugs.
Coulombe F, Divangahi M.
Expert Rev Anti Infect Ther. 2014 Nov;12(11):1337-43.

NLRX1 prevents mitochondrial induced apoptosis and enhances macrophage antiviral immunity by interacting with influenza virus PB1-F2 protein.
Jaworska J, Coulombe F, Downey J, Tzelepis F, Shalaby K, Tattoli I, Berube J, Rousseau S, Martin JG, Girardin SE, McCullers JA, Divangahi M.
Proc Natl Acad Sci U S A. 2014 May 20;111(20):E2110-9.

Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages.
Coulombe F, Jaworska J, Verway M, Tzelepis F, Massoud A, Gillard J, Wong G, Kobinger G, Xing Z, Couture C, Joubert P, Fritz JH, Powell WS, Divangahi M.
Immunity. 2014 Apr 17;40(4):554-68

N-glycolylated peptidoglycan contributes to the immunogenicity but not pathogenicity of Mycobacterium tuberculosis.
Hansen JM, Golchin SA, Veyrier FJ, Domenech P, Boneca IG, Azad AK, Rajaram MV, Schlesinger LS, Divangahi M, Reed MB, Behr MA.
J Infect Dis. 2014 Apr 1;209(7):1045-54. 

398-3864
ex.089727
398-7483

P. Metrakos; M.D. C.M. (McGill University)

Email: peter.metrakos [at] muhc.mcgill.ca (Dr. Peter Metrakos)

934-1934
ex. 31600
843 1503
 

 

   

M. Park; Ph.D. (Glasgow University, Scotland)

Email: morag.park [at] mcgill.ca (Dr. Morag Park)

Profile

Dr. Morag Park is a James McGill Professor in the Departments of Biochemistry, Medicine and Oncology at McGill University, where she holds the Diane and Sal Guerrera Chair in Cancer Genetics. She is also the current Scientific Director of the CIHR Institute of Cancer Research. Dr. Park has published over 100 papers in peer-reviewed journals. Her work has been recognized with numerous awards including becoming a Fellow of the Royal Society of Canada.

Research Interests
Dr. Park has a long standing interest in the molecular mechanisms of cancer. More recently her interests include how changes in the tumor microenvironment modulate breast cancer progression. She founded the Breast Cancer Functional Genomics Group, which integrates breast cancer sample collection, laser capture microdissection microarray-based gene expression profiling and signature validation, and includes members from basic research, informatics as well as clinical surgery and pathology.

 

Recent Publications

Deficiency of the chromatin regulator Brpf1 causes abnormal brain development.
You L, Zou J, Zhao H, Bertos NR, Park M, Wang E, Yang XJ.
J Biol Chem. 2015 Jan 7. pii: jbc.M114.635250.

Breast Cancer Anti-Estrogen Resistance-3 inhibits transforming growth factor-ß/Smad signaling and associates with favorable breast cancer disease outcomes.
Guo J, Canaff L, Rajadurai C, Fils-Aimé N, Tian J, Dai M, Korah J, Villatoro M, Park M, Ali S, Lebrun JJ.
Breast Cancer Res. 2014 Dec 13;16(6):476.

MS/MS-based strategies for proteomic profiling of invasive cell structures.
Havrylov S, Park M.
Proteomics. 2015 Jan;15(2-3):272-86.

Autocrine Activation of the Wnt/β-Catenin Pathway by CUX1 and GLIS1 in Breast Cancers.
Vadnais C, Shooshtarizadeh P, Rajadurai CV, Lesurf R, Hulea L, Davoudi S, Cadieux C, Hallett M, Park M, Nepveu A.
Biol Open. 2014 Sep 12;3(10):937-46.

p66ShcA promotes breast cancer plasticity by inducing an epithelial-to-mesenchymal transition.
Hudson J, Ha JR, Sabourin V, Ahn R, La Selva R, Livingstone J, Podmore L, Knight J, Forrest L, Beauchemin N, Hallett M, Park M, Ursini-Siegel J.
Mol Cell Biol. 2014 Oct 1;34(19):3689-701.

Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer.
Lai AZ, Cory S, Zhao H, Gigoux M, Monast A, Guiot MC, Huang S, Tofigh A, Thompson C, Naujokas M, Marcus VA, Bertos N, Sehat B, Perera RM, Bell ES, Page BD, Gunning PT, Ferri LE, Hallett M, Park M.
Sci Signal. 2014 Apr 22;7(322):ra38.

Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer.
Wallace JA, Li F, Balakrishnan S, Cantemir-Stone CZ, Pecot T, Martin C, Kladney RD, Sharma SM, Trimboli AJ, Fernandez SA, Yu L, Rosol TJ, Stromberg PC, Lesurf R, Hallett M, Park M, Leone G, Ostrowski MC.
PLoS One. 2013 Aug 16;8(8):e71533.

398-5749 398-6769

A. Schwertani; M.D. C.M., Ph.D. (London)

Email: adel.giaid [at] mcgill.ca (Dr. Adel Schwertani (Giaid))

934-1934
Ex. 43841
 

Sabah N.A. Hussain, M.D. Ph.D.  Critical Care and Respiratory Divisions

Email: sabah.hussain [at] muhc.mcgill.ca (Dr. sabah Hussain)

Profile

Dr. Sabah Noori Abdul Hussain is a James McGill Professor in the Department of Medicine ,( Critical Care and Respiratory Divisions appointed since July 1st, 2005); Medical Director at Pulmonary Function Laboratories since july 1999  and the Research Director at Meakins-Christie Labs of the MUHC since july 1991. Dr. Hussain joined the Department of Pathology as an associate member in 2017. 

Research Interests and selected publications

Dr. Hussain is currently involved in three main areas of research. First, his laboratory is currently investigating molecular signaling pathways and mechanisms of action of angiogenesis factors in general and angiopoietins and Tie-2 receptors in particular. Current project include identification of transcription factor networks downstream from Tie-2 receptors both in endothelial cells and in cultured skeletal muscle satellite cells. In addition, his laboratory is exploring the biological functions of both angiopoietin-1 and angiopoietin-2 in regulating cytokine cascade and tissue injury in various models of inflammation including severe sepsis and acute lung injury. To achieve the objective in this area of research his laboratory has developed transgenic animal models to over-express angiopoietins selectively in the vasculature. His second area of research is the biological roles of angiopoietins in skeletal muscle regeneration with particular emphasis on ventilatory muscle function. In this regard, we are investigating the effectiveness of gene therapy in which angiopoietins are delivered in vivo in various models of skeletal muscle injury and regeneration including cardiotoxin necrosis model and mdx model of Duchenne Muscular Dystrophy. His third area of research interest is molecular mechanisms involved in skeletal muscle atrophy in general and regulation of autophagy and proteosomal pathways in particular. Current research project include assessing the contribution of autophagic pathway to skeletal muscle protein degradation in human diaphragm during mechanical ventilation.

Fibulin-5 Regulates Angiopoietin-1/Tie-2 Receptor Signaling in Endothelial Cells
Chan Wilson, Ismail Hodan, Mayaki Dominique, Sanchez Veronica, Tiedemann Kerstin, Davis Elaine C, Hussain Sabah N A,
PloS one, Volume 11, Issue 6, e0156994 (June 15, 2016)

Prolonged controlled mechanical ventilation in humans triggers myofibrillar contractile dysfunction and myofilament protein loss in the diaphragm
Hussain Sabah N A, Cornachione Anabelle S, Guichon Céline, Al Khunaizi Auday, Leite Felipe de Souza, Petrof Basil J, Mofarrahi Mahroo, Moroz Nikolay, de Varennes Benoit, Goldberg Peter, Rassier Dilson E, 
Thorax, Volume 71, Issue 5, 436-45 (March 31, 2016)

Contribution of the Mitochondria to Locomotor Muscle Dysfunction in Patients With COPD
Taivassalo Tanja, Hussain Sabah N A,
Chest, Volume 149, Issue 5, 1302-12 (December 12, 2015)

Angiopoietin-1 inhibits toll-like receptor 4 signalling in cultured endothelial cells: role of miR-146b-5p
Echavarria Raquel, Mayaki Dominique, Neel Jean-Charles, Harel Sharon, Sanchez Veronica, Hussain Sabah N A, ,
Cardiovascular research, Volume 106, Issue 3, 465-77 (March 30, 2015)

Angiopoietin-1 enhances skeletal muscle regeneration in mice
Mofarrahi Mahroo, McClung Joseph M, Kontos Christopher D, Davis Elaine C, Tappuni Bassman, Moroz Nicolay, Pickett Amy E, Huck Laurent, Harel Sharon, Danialou Gawiyou, Hussain Sabah N A
American journal of physiology. Regulatory, integrative and comparative physiology, Volume 308, Issue 7, R576-89 (January 21, 2015)

Reactive oxygen species regulation of autophagy in skeletal muscles
Rahman Mashrur, Mofarrahi Mahroo, Kristof Arnold S, Nkengfac Bernard, Harel Sharon, Hussain Sabah N A, 
Antioxidants & redox signaling, Volume 20, Issue 3, 443-59 (2014)

Regulation of angiopoietin-1/Tie-2 receptor signaling in endothelial cells by dual-specificity phosphatases 1, 4, and 5,
Echavarria Raquel, Hussain Sabah N A,
Journal of the American Heart Association, Volume 2, Issue 6, e000571 (December 5, 2013)

Autophagic flux and oxidative capacity of skeletal muscles during acute starvation
Mofarrahi Mahroo, Guo Yeting, Haspel Jeffrey A, Choi Augustine M K, Davis Elaine C, Gouspillou Gilles, Hepple Russell T, Godin Richard, Burelle Yan, Hussain Sabah N A, 
Autophagy, Volume 9, Issue 10, 1604-20 (August 15, 2013)

Angiogenesis-related factors in skeletal muscles of COPD patients: roles of angiopoietin-2
Mofarrahi Mahroo, Sigala Ioanna, Vassilokopoulos Theodoros, Harel Sharon, Guo Yeting, Debigare Richard, Maltais Francois, Hussain Sabah N A, 
Journal of applied physiology (Bethesda, Md. : 1985), Volume 114, Issue 9, 1309-18 (January 10, 2013)

Muscle cell derived angiopoietin-1 contributes to both myogenesis and angiogenesis in the ischemic environment.
McClung Joseph M, Reinardy Jessica L, Mueller Sarah B, McCord Timothy J, Kontos Christopher D, Brown David A, Hussain Sabah N A, Schmidt Cameron A, Ryan Terence E, Green Tom D,
Frontiers in physiology, Volume 6, 161 (May 19, 2015)

Mechanisms of Chronic Muscle Wasting and Dysfunction after an Intensive Care Unit Stay. A Pilot Study
Dos Santos Claudia, Hussain Sabah N A, Mathur Sunita, Picard Martin, Herridge Margaret, Correa Judy, Bain Alexandra, Guo Yeting, Advani Andrew, Advani Suzanne L, Tomlinson George, Katzberg Hans, Streutker Catherine J, Cameron Jill I, Schols Annemie, Gosker H R, Batt J, 
American journal of respiratory and critical care medicine, Volume 194, Issue 7, 821-830 (October 1, 2016.

Failed reinnervation in aging skeletal muscle
Aare Sudhakar, Spendiff Sally, Vuda Madhusudanarao, Elkrief Daren, Perez Anna, Wu Qinghua, Mayaki Dominique, Hussain Sabah N A, Hettwer Stefan, Hepple Russell T,
Skeletal muscle, Volume 6, Issue 1, 29 (September 1, 2016)

9341934 Ext.
34645 (office)
36016 (lab)
76172(admin)
 

Fax:933-3962

Wassim Kassouf, MD, CM, FRCSC

email: wassim.kassouf [at] muhc.mcgill.ca (Dr. Wassim Kassouf)

 

Profile

After medical school and residency at McGill University, Dr Wassim Kassouf completed a urologic oncology fellowship at M. D. Anderson Cancer Center in Houston, Texas. He then arrived on faculty in August 2006 at the McGill University Health Center, Montreal, Canada.  He is a Professor in the Division of Urology and Vice-Chair, academic affairs, of the Department of Surgery at McGill University. Dr. Kassouf’s clinical practice focuses on bladder, prostate, and renal cancer.
He has led several national guidelines for optimizing quality of care in urologic cancer management and has published over 270 peer-review manuscripts and book chapters. He is the founder of the national Canadian Bladder Cancer Network, a co-founder of Bladder Cancer Canada (BCC), co-chair of the National Cancer Institute of Canada’s disease-oriented group in bladder cancer, and an executive member of the NIH Genitourinary steering committee Bladder Cancer Task Force. He has served as program director over the last 6 years and currently is a member of the Royal College Urology Examination board committee.  Dr Kassouf is a graduate of the AUA Leadership Program and received several awards including the American Urological Association Young Urologist of the Year, AUA Research Scholar Award, Canadian Urological Association Scholarship Award, FRSQ Clinician Scientist Research Scholar Award, and the Everett C. Reid Teaching Excellence Award. 

Research Interests and selected publications

His clinical and translational research focuses on the biology and therapy of bladder cancer.  His translational research over the recent years have been primarily on biomarkers and radiosensitization in bladder cancer. 

Phase I clinical trial of everolimus combined with trimodality therapy in patients with invasive bladder cancer
Bachir B, Souhami L, Mansure JJ, Brimo F, Vanhuyse M, Sturgeon J, Cury F, Aprikian A, Tanguay S, and Kassouf W
(Bladder Cancer, in press)

Radical Cystectomy is the best choice for most patients with muscle-invasive bladder cancer?
Monteiro LL, Kassouf W 
Int Braz J Urol. 2017 Mar-Apr;43(2):184-187.

Quality indicators in the management of bladder cancer: A modified Delphi study.
Khare SR, Aprikian A, Black P, Blais N, Booth C, Brimo F, Chin J, Chung P, Drachenberg D, Eapen L, Fairey A, Fleshner N, Fradet Y, Gotto G, Izawa J, Jewett M, Kulkarni G, Lacombe L, Moore R, Morash C, North S, Rendon R, Saad F, Shayegan B, Siemens R, So A, Sridhar SS, Traboulsi SL, Kassouf W.   
Urol Oncol. 2017 Jan 3. pii: S1078-1439(16)30410-0. doi: 10.1016/j.urolonc.2016.12.003

Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy
Gakis G, Black PC, Bochner BH, Boorjian SA, Stenzl A, Thalmann GN, Kassouf W.
Eur Urol. 2017 Apr;71(4):545-557. doi: 10.1016/j.eururo.2016.09.035. Review.

The role of HMGB1 in radio-resistance of bladder cancer
 Shrivastava S, Mansure JJ, Almajed W, Cury F, Ferbeyre G, Popovic M, Seuntjens J, Kassouf W
Mol Cancer Ther 15:471-9, 2016.

A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer.
Mansure JJ, Nassim R, Chevalier S, Szymanski K, Rocha J, Aldousari S, Kassouf W
PLoS One. 8(2):e55997, 2013

Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: a novel strategy for treatment
Nassim R, Mansure JJ, Chevalier S, Cury F, Kassouf W
PLoS One. 2013 Jun 17;8(6):e65257.

Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
Fahmy M, Mansure JJ, Brimo F, Yafi FA, Segal R, Althunayan A, Hicks J, Meeker A, Netto G, Kassouf W
Hum Pathol. 2013 Apr 23. doi:pii: S0046-8177(13)00078-6

Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study.
Bell MD, Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W.
World J Urol. 2016 Oct;34(10):1405-9. doi: 10.1007/s00345-016-1795-5.

Does teaching of robotic partial nephrectomy affect renal function and perioperative outcomes?
Cerantola Y, Ploussard G, Kassouf W, Anidjar M, Bladou F.
Urol Oncol. 2017 Jan 6. pii: S1078-1439(16)30408-2. doi: 10.1016/j.urolonc.2016.12.001

Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.
Aziz A, Dobruch J, Hendricksen K, Kluth LA, Necchi A, Noon A, Rink M, Roghmann F, Seiler R, Gontero P, Kassouf W, Shariat SF, Xylinas E; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology.
World J Urol. 2017 Jan 10. doi: 10.1007/s00345-016-1995-z. [Epub ahead of print] Review.

Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy.
Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, van Rhijn BW, Fransen van de Putte EE, Zareba P, Koskinen I, Kassouf W, Traboulsi SL, Kukreja JE, Boström PJ, Shayegan B, Pinthus JH.
J Urol. 2016 Dec;196(6):1627-1633. doi: 10.1016/j.juro.2016.06.017.

Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma.
Krabbe LM, Eminaga O, Shariat SF, Hutchinson RC, Lotan Y, Sagalowsky AI, Raman JD, Wood CG, Weizer AZ, Roscigno M, Montorsi F, Bolenz C, Novara G, Kikuchi E, Fajkovic H, Rapoport LM, Glybochko PV, Zigeuner R, Remzi M, Bensalah K, Kassouf W, Margulis V.
J Urol. 2017 Mar;197(3 Pt 1):580-589. doi: 10.1016/j.juro.2016.09.078.

Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction.
Redrow GP, Guo CC, Brausi MA, Coleman JA, Fernandez MI, Kassouf W, Keeley FX Jr, Margulis V, Raman JD, Roupret M, Shariat SF, Spiess PE, Thalmann GN, Matin SF.
J Urol. 2017 Feb;197(2):287-295. doi: 10.1016/j.juro.2016.03.194. Review.

Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC).
Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fernández MI, Kikuchi E, Chade DC, Babjuk M, Grollman AP, Thalmann GN.
World J Urol. 2017 Mar;35(3):379-387. doi: 10.1007/s00345-016-1928-x.

Impact of Implementing the Paris System for Reporting Urine Cytology in the Performance of Urine Cytology:  A Correlative Study of 124 Cases.
Hassan M, Solanki S, Kassouf W, Kanber Y, Caglar D, Auger M, Brimo F.
Am J Clin Pathol. 2016 Sep;146(3):384-90. doi: 10.1093/ajcp/aqw127.

Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank.
Kamat AM, Agarwal P, Bivalacqua T, Chisolm S, Daneshmand S, Doroshow JH, Efstathiou JA, Galsky M, Iyer G, Kassouf W, Shah J, Taylor J, Williams SB, Quale DZ, Rosenberg JE.
Bladder Cancer. 2016 Apr 27;2(2):203-213.

Neoadjuvant chemotherapy-related histologic changes in radical cystectomy: assessment accuracy and prediction of response.
Wang HJ, Solanki S, Traboulsi S, Kassouf W, Brimo F.
Hum Pathol. 2016 Jul;53:35-40. doi: 10.1016/j.humpath.2016.02.011.

Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study.
Eapen LJ, Jones E, Kassouf W, Lambert C, Morgan SC, Moussa M, Nam R, Parliament M, Russell L, Saad F, Siemens DR, Souhami L, Szumacher E, Tyldesley S, Xu Y, Zbieranowski I, Breau RH, Belanger E, Black P, Estey E, Bowan J, Bora B, Brundage M, Chung P, Fleshner N, Evans A, Bauman G, Izawa J, Davidson C, Brimo F.
Can Urol Assoc J. 2016 Mar-Apr;10(3-4):90-4. doi: 10.5489/cuaj.3456.

 

934-8246

934-8297

Goffredo Orazio Rinaldo Arena, MD, Chir. Vasc. (Ita), FRCS(C),

Email: goffredoarena [at] gmail.com (Dr. Goffredo Orazio Rinaldo Arena, MD)

Profile

Dr. Goffredo Arena graduated in Italy at the University of Catania in 1997.  He then moved to England where he started his training in General and Vascular Surgery at the Royal Free Hospital in London. In 2003 he transferred to McMaster University in Hamilton to continue his training in General and Vascular Surgery. In 2006 he gained the Vascular Surgery fellowship Certificate in Italy and in 2007 he obtained his General Surgery Specialist Certificate in Canada and he became a fellow of the Royal College of Surgeons. In 2007 he relocated to Montreal and he completed back to back a fellowship in Minimally Invasive Surgery and a fellowship in HPB and multi-organ transplantation at McGill University.

Research Interests and selected publications

His main research interest focus on horizontal transfer of malignant traits and he has become worldwide one of the main advocates of the genometastatic hypothesis.  He has patented a novel blood test called MATERD for cancer screening and metastatic recurrence prediction. Recently he published on the reprogramming effect of human embryonic stem cells’ exosomes on cancer cells.

Transfer of malignant traits as opposed to migration of cells: A novel concept to explain metastatic disease.
Arena GO, Arena V, Arena M, Abdouh M.
Med Hypotheses. 2017 Mar;100:82-86. doi: 10.1016/j.mehy.2017.01.019

Reprogramming Malignant Cancer Cells toward a Benign Phenotype following Exposure to Human Embryonic Stem Cell Microenvironment.
Zhou S, Abdouh M, Arena V, Arena M, Arena GO.
PLoS One. 2017 Jan 9;12(1):e0169899. doi: 10.1371/journal.pone.0169899.

Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients.
Hamam D, Abdouh M, Gao ZH, Arena V, Arena M, Arena GO.
J Exp Clin Cancer Res. 2016 May 14;35:80. doi: 10.1186/s13046-016-0360-9
 

Kommerell's diverticulum and aneurismal right sided aortic arch: a case report and review of the literature. 
Cinà CS, Arena OG, Clase CM, Bruin G. 
Journal of Vascular Surgery 2000; 32: 1208-14

Ruptured mycotic thoracoabdominal aortic aneurysms: Three case reports and a systematic review. 
Cinà CS, Arena OG, Fiture AO, Clase CM, Doobay B. 
Journal of Vascular Surgery 2001; 33:861-7

Subclavian-carotido transposition to reconstruct the first portion of the subclavian artery: personal experience and review of the literature.
Cinà CS, Safar HA, Laganà A, Arena OG, Clase CM.
Journal of Vascular Surgery 2002; 35: 422-29

Cerebrospinal fluid drainage to prevent paraplegia during thoracic and thoracoabdominal aortic aneurysm surgery: A systematic review and a meta-analysis.
Hamam D, Abdouh M, Gao ZH, Arena V, Arena M, Arena GO.
Cina CS, Arena GO, et al.
Journal of Vascular Surgery 2004; 40: 36-44

The retrojugular approach to carotid endarterectomy- A safer technique?
Menon NJ, Krijgsmann B, Sciacca L, Arena GO, Hamilton G.
Journal of Vascular and Endovascular Surgery 2005; 29 (6):608-10

Laparoscopic versus open resection for colorectal cancer: a meta-analysis of oncologic outcomes.
Jackson TD, Kaplan GG, Arena G, Page JH, Rogers SO Jr
J Am Coll Surg 204:439–446 (2007)

Laparoscopic vs. open resection for colorectal cancer: A meta-analysis of oncologic outcomes
Jackson T.D.,  Kaplan G.G.,  Arena G., Page J.H.,  Rogers S.O.
Journal of Surgical Research February 2007 (Vol. 137, Issue 2, Page 248)

Staged hepatectomy for bilobar colorectal hepatic metastases
Jamal MH, Hassanain M, Chaudhury P, Tran TT, Wong S, Yousef Y, Jozaghi Y, Salman A, Jabbour S, Simoneau E, Al-Abbad S, Al-Jiffry M, Arena G, Kavan P, Metrakos P.
HPB (Oxford). 2012 Nov;14(11):782-9. doi: 10.1111/j.1477-2574.2012.00543.x. Epub 2012 Aug 26.

 

 

483 5101

482 4342

Nada Jabado, MD, PhD

nada.jabado [at] mcgill.ca (E-mail: Dr. Nada Jabado)

 Profile

Dr. Nada Jabado is a Professor of Pediatrics and staff physician in the Department of Hematology and Oncology at the Montreal Children’s Hospital. She completed her residency in pediatrics with a specialization in hemato-oncology, obtained a PhD in Immunology in Paris and followed that by a postdoctoral fellowship in biochemistry at McGill. She began her career as an independent investigator at The Research Institute of the McGill University Health Centre in 2003, pioneering a research program in pediatric brain tumours which is now unparalleled. Her group uncovered that pediatric high-grade astrocytomas (HGA) are molecularly and genetically distinct from adult tumours. More importantly, they identified a new molecular mechanism driving pediatric HGA, namely recurrent somatic driver mutations in the tail of histone 3 variants (H3.3 and H3.1) at amino acid positions K27 (Lysine to Methionine, K27M) and G34 (Glycine to Valine or Arginine, G34V/R). A true clinician-scientist, Dr. Jabado leads a lab comprised of 6 postdoctoral and clinical fellows, 6 graduate students and 5 research assistants/associates.  Her ground-breaking work has created a paradigm shift in cancer with the identification of histone mutations in human disease for the first time. This finding has revolutionized the field, as the epigenome was a previously unsuspected hallmark of oncogenesis, thus linking development and what we now know are epigenetic-driven cancers. This work and other publications in the subject are considered landmark papers (over 3000 citations since 2012).
Dr. Jabado has over 150 peer-reviewed publications to her credit, with an impressive number of senior-author, high-impact publications in such prominent journals as Nature Genetics, Nature, Science and Cancer Cell, to name a few. She established the ICHANGE (International CHildhood Astrocytoma Novel Genomic and Epigenomic) Consortium which groups researchers from 17 countries. This is a unique set of resources which enables the scientific community to explore pediatric brain tumors in depth with the ultimate aim of offering better therapeutic options by providing datasets, international collaborations and access to technology to all members of participating countries.
Dr. Jabado is an international leader in the field of neuro-oncology and cancer, honored by invitations as Keynote and Guest Speaker at top ranked symposia and universities. She has received numerous national and international accolades while garnering prestigious awards throughout her career. She is one of the best-funded investigators at McGill, with grants from CIHR, FRSQ, Genome Canada, NIH, a Large Scale Genomic grant from Genome Canada as well as funding from philanthropic organizations. She was recently inducted as a Fellow to the Royal Society of Canada. 
Dr. Jabado is part of a rare breed of physicians that can actively link research to the bedside, a true clinician scientist. Her dedication to scientific research in pediatric brain tumours and her passion for the patients in her care are inspiring and infectious to colleagues and trainees alike. Her coworkers describe her as The Tasmanian Devil, a moving force of nature that can uproot entire schools of thought with gale-force winds. Anyone who has witnessed her speak in public will also attest to this phenomenon. Legend has it that she lives on coffee and chocolates. Dr. Jabado considers downtime as time spent racing the ski slopes with her physician husband and three teenage children who are a family of avid skiers

 

Research Interests and selected publications

As an independent Principal Investigator, Dr. Jabado's has embarked on elucidating genetic signatures of pediatric astrocytomas and examining how they compare to adults. These are deadly brain tumours that originate in brain and include glioblastomas (GBM, the highest grade of astrocytomas), which are one of the deadliest cancers in humans.  Her group uncovered that pediatric high-grade astrocytomas (HGA) are molecularly and genetically distinct from adult tumors. They also identified a new molecular mechanism driving pediatric HGA, namely recurrent somatic driver mutations in the tail of histone 3 variants (H3.3 and H3.1). These mutations lead to amino acid substitutions at key residues and are tightly correlated with a distinct global DNA methylation pattern, neuroanatomical locations and age specificities. Their findings position them as leaders in the field of HGA, at the forefront of significant breakthroughs for this deadly brain tumor. Crucial impediments to progress are the lack of reliable in vitro and in vivo models for these “oncohistones” and understanding their effects in driving tumors and therapeutic resistance. they aim to identify events affected downstream of each mutation, and validate targets in their new models to better advise the use of experimental or pipeline drug(s) or drug combinations that could be rapidly translated into clinical trials. Ultimately, based on their findings, patients could be stratified based on their genetic/molecular signature, and assigned to a beneficial therapeutic strategy, bringing needed effective interventions in this devastating cancer. Additionally, they established a TCGA-like initiative by creating the International CHildhood Astrocytoma INtegrated Genomic and Epigenomic (ICHANGE) Consortium. This is a unique set of resources which enables the scientific world to investigate astrocytomas in children. It includes databases and access to technology as well as international collaborations from 15 participating countries, including ~1500 annotated glioma tissue samples representative of all grades and ages.

Diffuse intrinsic pontine gliomas -current management and new biologic insights. Is there a glimmer of hope?
Cohen KJ, Jabado N, Grill J
Neuro Oncol. 2017 Mar 24. doi: 10.1093/neuonc/nox021.

Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature.
Fossey M, Li H, Afzal S, Carret AS, Eisenstat DD, Fleming A, Hukin J, Hawkins C, Jabado N, Johnston D, Brown T, Larouche V, Scheinemann K, Strother D, Wilson B, Zelcer S, Huang A, Bouffet E, Lafay-Cousin L
J Neurooncol. 2017 Mar;132(1):155-162. doi: 10.1007/s11060-016-2353-0.

Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas
Papillon-Cavanagh S, Lu C, Gayden T, Mikael LG, Bechet D, Karamboulas C, Ailles L, Karamchandani J, Marchione DM, Garcia BA, Weinreb I, Goldstein D, Lewis PW, Dancu OM, Dhaliwal S, Stecho W, Howlett CJ, Mymryk JS, Barrett JW, Nichols AC, Allis CD, Majewski J, Jabado N.
Nat Genet. 2017 Feb;49(2):180-185. doi: 10.1038/ng.3757

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.
Torchia J, ......, Jabado N, Huang A
Cancer Cell. 2016 Dec 12;30(6):891-908. doi: 10.1016/j.ccell.2016.11.003.

Longitudinal mutational analysis of a cerebellar pilocytic astrocytoma recurring as a ganglioglioma.
Fiset PO, Fontebasso AM, De Jay N, Gayden T, Nikbakht H, Majewski J, Jabado N, Albrecht S
Pediatr Blood Cancer. 2017 Feb;64(2):275-278. doi: 10.1002/pbc.26215

Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape.
Lu C, Jain SU, Hoelper D, Bechet D, Molden RC, Ran L, Murphy D, Venneti S, Hameed M, Pawel BR, Wunder JS, Dickson BC, Lundgren SM, Jani KS, De Jay N, Papillon-Cavanagh S, Andrulis IL, Sawyer SL, Grynspan D, Turcotte RE, Nadaf J, Fahiminiyah S, Muir TW, Majewski J, Thompson CB, Chi P, Garcia BA, Allis CD, Jabado N, Lewis PW.
Science. 2016 May 13;352(6287):844-9. doi: 10.1126/science.aac7272.

934-1934
ex 76163

933-4673